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The serendipitous discovery of the anti-proliferative effects of cisplatin by Barnett 
Rosenberg in 1965 has since saved the lives of thousands of patients with cancer. 
Platinum-based anticancer agents, such as cisplatin, carboplatin and oxaliplatin, 
have been indispensable in the treatment of many cancers for several decades. 
However, in recent years, a higher number of patients have developed intrinsic or 
extrinsic resistance to platinum-based chemotherapy, and the severe side effects 
borne by patients undergoing platinum-based treatment regimens has spurred the 
need for platinum agents with better patient tolerability and improved anti-tumoral 
efficacy.  
 
Platinum(IV) anticancer drugs offer a “prodrug strategy” that not only circumvents 
the resistance encountered in platinum-based chemotherapy, but also leads to 
improved tolerability in patients. However, while thousands of platinum(IV) 
complexes have been synthesized to date, only four have made it into clinical trials, 
and three out of four have failed to show clinical efficacy that supersedes the 
currently accepted regime. These compounds, however, have provided key insight 
into the mode of action of platinum agents, which appear to depend on the stability 
and rate and degree of cellular accumulation in the cell. To that end, this thesis 
sought to examine the properties of platinum(IV) complexes important for their 




The cytotoxicity of platinum-based anticancer drugs has been correlated to the level 
of platination on the DNA; hence, higher cellular platinum accumulation could 
potentiate an increase in the formation of platinum-DNA adducts and result in 
better activity against cancer cells. In this thesis, it was hypothesized that 
cytotoxicity can be increased with the use of high lipophilic platinum(IV) 
complexes which increase the cellular accumulation of the drug and enhance the 
formation of platinum-DNA adducts. To explore this further, Chapter 2 focusses 
on the relationship between lipophilicity and cellular platinum accumulation, 
comparing platinum(IV) complexes that are asymmetric and symmetric in their 
design. The attachment of asymmetrical axial ligands allowed fine-tuning of the 
lipophilicity of platinum(IV) complexes, and this lead to an increase in cellular 
platinum accumulation in the two ovarian cancer cell lines studied. The use of 
several assays indicated that this cellular uptake of the platinum(IV) complexes 
were mediated by energy-independent pathways. The same hypothesis is further 
studied in Chapter 3 to explore the mode of action of these lipophilic platinum(IV) 
complexes in relation to the enhanced cellular accumulation of the drug. The 
platinum(IV) complexes induced cell cycle arrest at G2/M phase and apoptotic cell 
death in ovarian cancer cells. Surprisingly, the dependence of platinum(IV) 
complexes on p53 to initiate the apoptotic signaling decreased as lipophilicity 
increased.  
 
Protein expression analyses and cellular accumulation studies are often used to 
study the mode of action of platinum complexes. The study can be complement by 
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cellular tracing of platinum complexes via fluorescence imaging. Thus, a 
fluorescent probe, Rho-DDTC, was used to map the fate of platinum complexes in 
cells. Rho-DDTC retained its specificity in the complex cellular environment and 
selectively detected cisplatin and the platinum(II) species that form upon reduction 
of the platinum(IV) prodrug complexes. The results showed that PtBz accumulates 
around the nucleus, which promotes the formation of platinum-DNA adducts. This 
complements the findings in Chapters 2 and 3 where PtBz exhibit superior 
cytotoxicity than its parental drug cisplatin.  
 
Good in vitro efficacy of a drug does not necessarily translate into good in vivo 
activity, as there are numerous other factors that contribute to the outcome in vivo. 
Consequently, other physicochemical properties, such as solubility, rate of 
reduction, and aqueous stability, are equally important as in vitro cytotoxicity when 
selecting a compound for in vivo and clinical evaluation. Therefore, in Chapter 5, 
the relationship between the physicochemical properties and in vivo activity was 
studied using three asymmetric-platinum(IV) complexes (A3, A9 and A14) in a 
colitis-induced model of colorectal cancer in mice. Each of these three complexes 
showed good cytotoxicity, solubility, aqueous stability, and slow rate of reduction 
in vitro, and were evaluated and compared with satraplatin in the mouse model. 
Overall, complex A14 showed the best performance in treating colorectal cancer 




Cisplatin-based drugs will continue to offer excellent anti-cancer properties, 
assuming that the current limitations associated with the drug and its delivery can 
be circumvented. The outcome of this study highlights the importance of assessing 
solubility, stability, reduction rate, and toxicity when determining drug in vivo 
efficacy. The findings of this study demonstrate the utility of the prodrug approach 
for the delivery of anti-cancer agents, and will hopefully help to pave the way in 
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Cancer is a major cause of mortality worldwide and the number of deaths due to 
cancer is estimated to be close to 24 million by the year 2035.1,2  The conventional 
treatment options for cancer include combinations of surgery, radiotherapy, 
chemotherapy, hormone therapy, immunotherapy and bone marrow and stem cell 
transplantations, with the treatment selected based on the Stage of cancer, patient 
characteristics and a host of other determining factors.2 Localized, primary tumors 
are best treated with surgery. For instance, surgical treatment for patients with Stage 
I non-small cell lung cancers achieves a 58% to 73% survival rate for 5 years or 
more.3 However, cancer is usually diagnosed late in its progression after having 
advanced into a Stage III/IV metastatic cancer.4  
 
Cancer metastasis—defined as the spread of cancer from its origin to another tissue 
or organ, with the possibility to form a secondary tumor at the new site—is the main 
cause of death from cancer, and this hallmark of cancer continues to remain a 
challenge in the clinic in terms of providing patients with definitive treatment plans. 
Although surgery and radiation therapy can achieve high survival rates, their 
application is limited to localized primary tumors. Metastatic cancers, on the other 
hand, require a systemic approach, which is currently delivered in the form of 
chemotherapy, hormone therapy and immunotherapy.5 Among the 
2 
 
chemotherapeutic agents available, platinum-based therapeutic agents, such as 
cisplatin, carboplatin and oxaliplatin, have been the mainstay treatment agent for 
various cancers over the past several decades.6,7,8 Their use was brought about by 
the efficacy of cisplatin in the treatment of testicular cancer, which sparked the 
application of heavy metals as an option for anticancer treatment.9,10  
 
 
Figure 1.1. Platinum-based anticancer drugs with clinical approval. 
 
1.2 Cisplatin 
Cis-diamminedichloroplatinum (II) (cis-Pt(NH3)2Cl2), cisplatin, cis-DDP, cDDP), 
was first synthesized in 1844 by Michel Peyrone.11 Platinum, arsenic, antimony and 
ruthenium complexes have been studied for their antibacterial activities since 
1953.11 However, neuromuscular toxicity impeded the topical application of 
ruthenium complex’s in the clinical setting; thereafter, little attention was paid to 
the study of metal complexes as medicinal drugs.11 It was only in 1965 when 
Barnett Rosenberg, a biophysicist, noticed that cisplatin could stop cell division in 
bacteria that the compound was tested for its similar properties against cancer 
3 
 
cells.12,13 The usage of cisplatin as an anticancer agent first began in clinical trials 
in 1971 and was granted FDA approval in 1979.11 Today, cisplatin can be used 
alone or in combination with other drugs to treat cancers including sarcoma, small 
cell lung cancer, germ cell tumors, lymphoma, and ovarian cancer.14,15,16  
 
1.2.1 Cellular uptake mechanism 
Although the antitumoral activity of cisplatin was identified 50 years ago, how it is 
taken up into the cell remains the subject of debate. Early results suggested that the 
neutral, intact cisplatin crossed the cellular membrane via passive diffusion, as the 
uptake of the drug was linear, non-saturable and only limited by the solubility of 
the complex.17,18,19 Furthermore, the cellular accumulation of cisplatin was not 
competitively inhibited by structural analogues or other compounds.19,20 These 
attributes provided strong support for the passive diffusion mechanism for the 
cellular accumulation of cisplatin, and these findings correlated with those of 
others.21,22,23  
 
In recent years, however, there is growing evidence to suggest that cisplatin 
accumulation can also be facilitated by multiple membrane transporters. It was 
noted that cisplatin accumulation was reduced when cells were incubated with 
various protein inhibitors that deactivate active transporters (benzaldehyde, 
pyridoxal, and pyridoxal 5’-phosphate).24,25 Later, in 1991, one study showed that 
the accumulation of cisplatin was lowered by 50% when cells were pre-incubated 
with an inhibitor of the membrane transporter Na+, K+-ATPase.26 However, the 
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involvement of the Na+, K+-ATPase in cisplatin uptake was challenged by the 
finding that cisplatin binds to the Na+, K+-ATPase and inhibits its activity.27,28 Thus, 
inhibition of the Na+, K+-ATPase would trigger an influx of Na+ ions, create a 
slightly positive membrane potential, and, in turn, disfavour cisplatin 
accumulation.28  
 
Another cellular transporter, the copper transporter 1 (Ctr1), has been linked with 
the cellular uptake of cisplatin. Studies showed that cells resistant to high levels of 
copper were also cross-resistant to cisplatin.29,30 It was postulated that platinum 
drugs enter the cells by hijacking the copper-transport system. Resistance to 
cisplatin treatment upon deletion of the Ctr1 gene provided further evidence for the 
involvement of Ctr1 in cisplatin uptake.31,32 Nevertheless, these results were 
contested by later work showing that an increase in Ctr1 expression had limited 
correlation with an increase in the uptake of cisplatin or the rate of cell death.33,34  
 
1.2.2 Mechanism of action 
The exact mechanism of cisplatin is still unknown, despite its use in the clinical 
setting for more than four decades. Nevertheless, DNA is still believed to be the 
main cellular target of cisplatin, where the signal cascade begins with DNA damage 
and ends with apoptotic cell death.35 Cisplatin is hydrolysed rapidly in the cell due 
to low intracellular chloride levels to two active Pt(NH3)2Cl(H2O)
+ and 
Pt(NH3)2(H2O)2
2+ species36,37, which form cross-links with the DNA.38,39 Specific 
DNA damage sensors recognize the formation of platinum-DNA adducts and signal 
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to downstream effectors to induce cell cycle arrest, DNA repair, and cell 
death.40,41,42  
One of the major signalling pathways activated by cisplatin-induced DNA damage 
is mediated by ataxia telangiectasia mutated (ATM) and ATM Rad3-related protein 
(ATR). ATR activates p53 protein and other downstream targets, such as 
checkpoint kinase 1 (CHK1) and mitogen-activated protein kinase (MAPK).43,44,45 
p53 also induces the expression of genes associated with cell cycle arrest, DNA 
repair and apoptosis, including the cyclin-dependent kinase inhibitor p21 
(p21Waf1/Cip1), growth arrest and DNA damage inducible alpha (Gadd45a), E3 
ubiquitin-protein ligase (MDM2) and Bcl-2 associated X (Bax).46,47 DNA repair 
that is deemed unsuccessful by the cell prompts the activation of apoptosis via the 
mitochondrial pathway, where pro-apoptotic proteins Bax and Bak activate the 
caspase 9-caspase 3 apoptosis pathway.48,49 
 
Recent studies also show that cisplatin is capable of inducing nuclear-independent 
apoptosis via the endoplasmic reticulum stress pathway and extrinsic pathway 
mediated by CD95 receptor/ligand system.50,51,52,53 Studies also indicate that 
cisplatin induces two modes of cell death, which is determined based on the 
cisplatin concentration, the cellular ATP level, and the status of the apoptotic 
machinery in the cell.54,55,56 It is postulated that excessive DNA damage activates 
poly(ADP-ribose) polymerase (PARP), which cleaves NAD+ and lowers cellular 
ATP levels to initiate necrosis; this pathway is thought to occur well before the 




Treatment with cisplatin has dose-limiting side effects and patients often develop 
intrinsic or acquired resistance. Patients face mild to severe toxicities in response 
to cisplatin treatment, such as ototoxicity, neurotoxicity and nephrotoxicity.58,59 
Ototoxicity—toxicity to the hearing or ear—is observed in 75% to 100% of patients 
receiving cisplatin treatment.60,61,62 Patients commonly report hearing loss in the 
high frequency, and the effect appears to be cumulative and usually irreversible.63,64 
The exact cause of ototoxicity is unclear but is commonly attributed to cisplatin-
induced damage to the outer hair cells of the cochlea and the spiral ganglion 
cells.65,66 Despite numerous in vitro and in vivo evaluations to identify protecting 
agents to prevent this toxicity (sodium thiosulfate, methionine, n-acetyl cysteine 
and α-tocopherol) none have demonstrated any clinical relevance to date.66  
 
Patients receiving cisplatin treatment also commonly suffer from 
nephrotoxicity.58,67 Clearance of cisplatin mainly occurs via the kidney, where it is 
taken up by the proximal tubule cells.68,69 Prolonged exposure to high 
concentrations of cisplatin causes kidney damage and, eventually, 
nephrotoxicity.70,71 While the search for the exact mechanism is still on-going, 
cisplatin-induced nephrotoxicity has been shown to worsen with dose and the 
duration of treatment.67 Nevertheless, nephrotoxicity in cisplatin treatment can be 




Cisplatin-induced neurotoxicity, in the form of peripheral neuropathy, is the main 
dose-limiting toxicity in cisplatin treatment.75 Dorsal root ganglia within the central 
nervous system are thought to be the primary site for damage, as high levels of 
platinum has been found to accumulate in this tissue.76,77,78 Peripheral neuropathy 
is also dose-dependent, cumulative and, presumably, permanent.79,80 Cures for 
cisplatin-induced neurotoxicity have yet to be found, with clinical trials ongoing.81  
 
These various toxicities from cisplatin treatment often require that the drug is 
administered in a lower dose but for a longer time. However, treatment with a 
dosage lower than the effective dose often results in incomplete cancer regression 
and later resistance to cisplatin treatment. The mechanism of cisplatin resistance 
has been studied extensively, as indicated by the reduced cellular accumulation of 
the compound in many cell lines in vitro. Other resistant cell lines show deletion or 
mutation of the CTR1 gene and modulation of the plasma membrane.31,82,83,84 In 
addition, the copper-transporting P-type adenosine triphosphate (ATP7A and 
ATP7B) and multi-drug resistance proteins (MRP1, MRP2 and MRP5) modulate 
sensitivity to cisplatin by increasing efflux.85,86,87,88 Furthermore, the inactivation 
of intracellular cisplatin by metallothioneins and glutathione also desensitize cells 
toward cisplatin treatment.89,90,91 The net effect of a reduced uptake, an increased 
efflux and the onset of cellular detoxification will reduce the cellular cisplatin level 




Resistance may also occur after the formation of platinum-DNA adducts through 
DNA repair strategies or as a result of increased tolerance to the DNA damage. In 
general, there are four pathways responsible for DNA repair: base-excision repair 
(BER), double-strand-break repair, mismatch repair (MMR) and nucleotide-
excision repair (NER).6 Platinum-DNA damage is primarily repaired through 
activation of the NER pathway, with the associated proteins excision repair cross-
complementing-1 (ERCC1) and xeroderma pigmentosum complementation group 
F (XPF).92 A high correlation has been found between NER protein expression in 
the tumor and patients’ response to platinum-based chemotherapy.93,94,95,96 Some 
resistant cells also harbour an increased tolerance to platinum-induced DNA 
damage by downregulating the MMR pathway. Aside from recognizing and 
repairing damaged DNA, the MMR pathway is also associated with the activation 
of downstream activators of apoptosis.97 Thus, MMR downregulation de-sensitizes 
the cells to cisplatin, and this is one of the types of resistance methods faced in 
patients with ovarian carcinoma.98,99,100  
 
Resistance after platinum-DNA binding can be mediated by multiple proteins, such 
as p53, CD95, Bax, Bcl-2, Bcl-xL, XIAP, PI3-K, NF-κB and c-myc.101 Modulation 
of these proteins affects the activation of apoptotic signalling pathways. p53 protein 
has been extensively studied due to its pivotal role in cell cycle arrest and 
apoptosis.47 Deletion or mutation of p53 causes a loss in apoptotic function, which 
in turn increases cellular tolerance to DNA damage.102,103 Indeed, there is a high 
correlation between p53 function and resistance to cisplatin in germ cell tumors, 
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ovarian, head and neck, and bladder cancers.35 Despite the high correlation between 
p53 function and cisplatin sensitivity, p53 is not used as a prognostic biomarker for 
evaluating chemotherapy response in the clinic, as no correlation was found in other 
cancer-types.104,105   
 
1.3 Cellular detection of cisplatin and platinum-based anticancer drug 
Much research has been done to gain a better understanding of cisplatin and its 
mechanism of action. The ability to determine platinum localization and measure 
its content within the cell is important, as it helps to shed light on the various 
mechanisms of cellular transport, resistance and toxicity induced by cisplatin. 
Cisplatin is difficult to trace, as it has low absorptivity in UV light, and no natural 
fluorescence. Nevertheless, the use of elemental imaging has enabled cisplatin to 
be traced within the cell, and this has been enhanced by the use of fluorescence 
imaging, which uses a fluorophore-tagged cisplatin or fluorescence probes that are 
specific for the drug to monitor the drug in real time.  
 
1.3.1 Elemental imaging of platinum complexes 
The cellular distribution of platinum can be readily quantified with elemental 
analyses, such as graphite furnace atomic absorption spectrometry (GF-AAS) and 
inductively coupled plasma mass spectrometry (ICP-MS).106,107,108 Such techniques 
allow for the detection and quantification of platinum at the sub-ppb level, by 
analysing cells and/or digested tissue samples. Hence, because the cells and tissues 
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need to be destroyed, such techniques are unable to monitor the localization of 
platinum in real time.109  
 
The electron-dense nature of platinum makes it a suitable element for imaging by 
electron microscopy, and the cellular accumulation of cisplatin in A2780 human 
ovarian carcinoma has been studied using this approach. Platinum was localized to 
the plasma membrane and nuclear envelope, as well as within the cytoplasm and 
the nuclear matrices.110 Since no intracellular vesicles were observed, the authors 
concluded that cisplatin was transported into the cells via passive diffusion and 
endocytosis-independent membrane translocation mechanisms.  
 
 
Figure 1.2. Electron microscopy images of A2780 cells treated with cisplatin (30 µg/mL) for 
different incubation times. (A) Platinum deposits make blunt contact with the plasma membrane, 
×40,000. (B) Platinum deposits spanning through the plasma membrane, ×40,000. (C) Platinum 
deposits spanning through the nuclear envelope, ×30,000. (D) Large platinum deposits contact the 
plasma membrane through several spike-like structures, ×67,000. (E) Nucleolus with abundant 




X-ray absorption spectroscopy (XAS) is a useful technique for determining the 
identity of a chemical species. The core-shell electrons of an atom are probed by x-
rays. Atoms at different oxidation states and geometries will absorb x-rays at 
distinct energies.111 The identity of an atom can then be determined by comparing 
the absorption profiles. XAS has been used to study cisplatin since 1978, where 
extended x-ray absorption fine structure spectroscopy (EXAFS) was applied to 
study the binding of cisplatin to calf thymus DNA.112 In this study, the authors 
observed that no Pt-Pt bonds were formed when cisplatin interacted with DNA, a 
critical piece of information that suggested that cisplatin binds to DNA in 1:1 ratio, 
with  no oxidation of the platinum centre observed.112  
 
Another technique, X-ray near edge adsorption spectroscopy (XANES), has also 
been applied to study the oxidation state of platinum and its distribution in cells. 
These studies showed that platinum(IV) reduction occurred mainly intracellularly, 
with correlation to their reduction potentials and cytotoxicity. Similar studies 
conducted thereafter further clarified that platinum accumulation in the cells 
correlated to the functional group of the axial ligands and the reduction 
potential.113,114  
 
Nano-scale secondary ion mass spectrometry (Nano-SIMS) has also been 
employed to assess the localization of cisplatin and other platinum compounds. 
Imaging by SIMS involves the colliding of high-energy ion beams onto the sample, 
which, in turn, causes the sputtering of materials (electrons, atoms and molecules) 
12 
 
that are extracted into a mass spectrometer for analysis.115  The analysis usually 
involves labelling of platinum complexes with 195Pt and 15N.115,116 The application 
of Nano-SIMS provides information as to the uptake and cellular localization of 
platinum compounds, and ligand exchange can be determined by comparing the 
localization profile of 195Pt and 15N. Cisplatin was found to accumulate in the 
nucleus and within acidic organelles in the cytoplasm, and this discrete localization 
pattern may help to explain its toxicity.116  
 
 
Figure 1.3. Secondary ion maps of a fixed section of SW480 cells treated with cisplatin (25 mM, 
24h). (A) The screened region is marked with a frame in the different interference contrast image of 
the cell. The confocal microscopy image of the (19F labelled) Lyso-Tracker Red (D) demonstrates a 
correlation with the signal intensity patterns of both 19F originating from LysoTracker Red (B) and 
194Pt originating from cisplatin (C) detected by NanoSIMS in the same cells. Arrows indicate a few 
regions of platinum accumulation without fluorescence and 19F signal intensity enhancement (2 out 
of 20 labelled area). Secondary ion signal intensities are displayed on a rainbow false-colour scale 
ranging from dark blue to red for low to high intensities, respectively. Scale bars = 5 µm. 
Reproduced with permission from ref 116. Copyright 2014 The Royal Society of Chemistry (Creative 




1.3.2 Fluorescence imaging of platinum complexes 
Cellular imaging techniques that incorporate fluorescence microscopy have been 
the most popular tool for studying platinum drugs, which are tagged with 




Figure 1.4. Distribution of FDDP as a function of time in 2008 cells. Cells were treated with 2 µM 
of FDDP (green) for 0, 2, 5, 10, 20 and 30 min, fixed and co-stained with Alexa Fluor 647 phalloidin 
(red, labelling of actin filaments). Overlap between FDDP and actin signals is represented in yellow. 
Adapted from ref 
117
. Copyright 2005 American Association for Cancer Research. 
 
For platinum detection, a fluorescein-tagged diamminedichloroplatinum (FDDP) 
molecule was designed, and this compound contributed significantly to our 
understanding of the cellular processing of platinum.117 FDDP exhibits similar IC50 
values as that of cisplatin in human ovarian carcinoma 2008 cells. The cisplatin-
resistant sub-line, 2008/C13*5.25, showed a profile of reduced accumulation over 
time, similar to that of cisplatin, thus indicating that FDDP was a suitable 
fluorescence candidate to model cisplatin action. Furthermore, the distribution of 
FDDP was different from that of the free fluorescein ligand, suggesting that the 
fluorescence observed in FDDP-treated cells represented the location of FDDP 
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rather than that of the free-floating ligand. Given the similar distribution profile of 
FDDP and cisplatin, FDDP is thus able to shed light on the secretory pathway and 
resistance mechanisms in cisplatin-resistant cells. 
 
Fluorophores have also been used to monitor the redox reaction of platinum(II) and 
platinum(IV) complexes in cells. Fluorescence coumarin-tagged platinum(II) is 
oxidized to platinum(IV), and the oxidation state of platinum can be differentiated 
by fluctuations in fluorescence intensity, as the fluorescence signal is quenched 
when platinum(II) is oxidized to platinum(IV).120 However, coumarin-tagged 
platinum shares a similar distribution pattern as free coumarin ligands, posing some 
doubt as to the reliability of the results.  
 
 
Figure 1.5. Overlay confocal images of A2780 cells treated with coumarin ligand, platinum(II) and 
platinum(IV) (blue) for 4 h with syto21 nuclear stain (green). Scale bars represent 10 mm. 




Aside from tagging platinum with a fluorophore, it is plausible to use click 
chemistry to post-label cellular platinum.121 NCI-H640 non-small-cell lung cancer 
cells were treated with a platinum(II) complex that had been modified with a stable 
amide-link azide derivative. After incubation with a platinum(II) complex, cells 
were fixed and treated with the alkyne-modified Alexa Fluor 488, where a click-
reaction occurred in the copper-based buffer. The observed higher fluorescence in 
the nucleus as compared with the cytoplasm supported the preferential 




Figure 1.6. Confocal images of platinum(II)-azide compound (5 µM) in fixed NCI-H460 cells after 
click reaction with Alexa Fluor 488-alkyne. Cell nuclei were stained with Hoechst 33342. 




The detection of platinum via elemental techniques such as ICP-MS has been a 
great tool in quantifying cellular platinum distribution. While these techniques 
allow for the detection of platinum down to sub-ppb level, it requires sacrificing 
intact cells and tissues.109 Using the electron dense nature of platinum, the detection 
of cellular platinum was advanced to electron microscopy imaging and, for the first 
time, cisplatin was able to be seen in cells.110 XANES and Nano-SIMS since then 
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further developed our understanding of the cellular mechanism of platinum drugs. 
However, despite the benefits provided by elemental imaging techniques, there is a 
risk of generating false results because of the tedious process of sample preparation. 
Samples are often treated with glutaraldehyde and organic solvents, and infiltrated 
with plastic resin prior to analysis, which can cause a redistribution of cellular 
contents and distort the results.122 
 
The issues faced in elemental imaging is not shared in fluorescence imaging. 
Fluorescence imaging of cellular platinum distribution is carried out with attached 
fluorophores. Being a small molecule that is without any carbon loading, any 
modification onto cisplatin would have an impact on its characteristics. The 
bulkiness of the fluorophore can significantly impact drug uptake characteristics, 
pharmacokinetics and the pharmacodynamics of the original drugs, rendering them 
different from cisplatin.119,123,124 There also lies a risk of the premature 
displacement of the fluorophore from platinum centre, meaning that the 
fluorescence signal obtained does not signify the location of platinum drug.118,120 
 
1.4 Platinum(IV) prodrug strategy 
The search for a new drug with better efficacy and pharmaco-toxicological profile 
than cisplatin began in the 1980s. This journey led to the discovery of second- and 
third-generation platinum anticancer agents, such as carboplatin, oxaliplatin, 
nedaplatin, heptaplatin and lobaplatin (Figure 1.1). Yet, the issues of premature 
aquation and inactivation are still faced in platinum-based chemotherapy.125 In 
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view of this, the idea of using inert platinum(IV) complexes as prodrug of 
platinum(II) anticancer agents has been proposed.  
 
Platinum(IV) complexes with d6 electron configuration are six-coordinated and 
adopt an octahedral structure. The saturated and kinetically inert platinum(IV) is 
less reactive as compared with platinum(II), reducing unwanted side reactions with 
biomolecules, and thus lowering its toxicity.126 Platinum(IV) prodrugs are 
generally designed as [Pt(IV)(L2)(X2)(A2)], with L representing any equatorial 
ammine ligands; X, any equatorial leaving groups such as chloride and oxalate, and 
A, the axial ligands. The additional axial ligands allow for fine tuning of the 
physicochemical and biological properties of platinum(IV), such as activity, 
stability, lipophilicity and selectivity. As platinum(IV) prodrugs are kinetically 
inert, they are assumed to be unreactive; however, studies have shown that 
platinum(IV) complexes form Pt-DNA adducts in their oxidized form.127,128 Having 
said this, the rate at which platinum(IV) platinates DNA into its oxidized form is 
much slower than that achieved by its platinum(II) congener. Hence, it is generally 
accepted that reduction of platinum(IV) to platinum(II) with the loss of two ligands 
is essential for the drug’s activity.129, The reduced platinum(II) species will then 





Figure 1.7. General structure of platinum(IV) prodrugs. Adapted from ref.130 Copyright 2014 The 
American Chemical Society.  
 
Structural activity relationship studies have shown that the reduction potential 
correlates with cytotoxicity. The reduction potentials of platinum(IV) complexes 
are dependent on their ligands, with axial ligands having a higher influence that 
equatorial ligands.131 In the series of cis,cis,trans-[Pt(L)(Cl2)(A2)] complexes, 
where L can be diaminocyclohexane, isopropylamine, cyclohexylamine or 
ethylenediamine, the reduction rate correlates with cytotoxicity and the increase in 
the order of the axial substitution; i.e., OH < OCOCH3 < Cl < OCOCF3.
131 A similar 
trend was observed in another diammine platinum(IV) [cis-Pt(en)Cl2X2] series, 
where reduction was found to occur most readily with chloro, followed by 
carboxylate, with hydroxo axial ligands proving the most difficult.132 Furthermore, 
the reduction potential was found to correlate with cellular platinum accumulation, 
which, in turn, affects the cytotoxicity of the drug.133 The increase in uptake is 
explained by the reduction and aquation of platinum(IV) complexes into active, 
positively charged species, which result in a reduced cellular efflux and a net 
increase in cellular accumulation. While cytotoxicity increases with reduction rates, 
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the design of platinum(IV) complexes that reduce readily is a double-edged sword. 
Take the example of tetraplatin, which contains axial chloride ligands. These 
ligands readily reduce in plasma and this leads to premature inactivation and severe 
neurotoxicity.15 Therefore, there lies a range within which the drug should be 
modulated for optimal reduction potential and subsequent drug efficacy.  
 
The activity of platinum(IV) complexes also correlates to lipophilicity. 
Lipophilicity of platinum(IV) complexes is often measured by the partition 
coefficient between n-octanol and water. Platinum(IV) complexes with high 
lipophilicity correlate positively with cytotoxicity due to the high cellular platinum 
accumulation. A quantitative structure-activity relationship performed on a series 
of platinum(II) and platinum(IV) complexes suggested that compounds with higher 
lipophilicity tend to show higher accumulation in cells.134 It has been postulated 
that lipophilic platinum(IV) complexes enter the cells passively. Thus, the 
formation of active, positively-charged platinum(II) species upon reduction and 
aquation, reduces efflux and results in a net increase in cellular platinum 
concentration. The relationship between lipophilicity and cytotoxicity was shown 
previously, when the anti-proliferative activity of a series of 
bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) compounds was 
found to correlate to their lipophilicity and cellular accumulation.135 The successive 
addition of methyl groups to the compound in the ester series significantly 
increased cellular accumulation and cytotoxicity. Independently, the same trend 
was observed in a series of bis(carboxylato)dichloridobis(ethylamine)platinum(IV) 
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complexes, where a linear relationship was found between lipophilicity and 
cytotoxicity.136 Nevertheless, care should be taken when designing platinum(IV) 
complexes with high lipophilicity, as the compound may be insoluble in water and 
face difficulties simply crossing the cellular membrane and become trapped within 
the cell membrane.    
 
1.4.1 Dual-purpose platinum(IV) complexes that release classical 
platinum(II) anticancer drugs and bioactive ligands 
Platinum(IV) functions as a versatile platform for the delivery of active platinum(II) 
species for anticancer activity. The additional axial ligands offer the opportunity to 
modulate the physical and biological properties of platinum(IV). In the recent years, 
there has been a paradigm shift in designing new platinum(IV) complexes, where 
bioactive molecules and targeting moieties are tethered to the platinum(IV) centre.  
 
Previous studies have noted that the expression of HMG domain-containing 
proteins is associated with the sensitivity of breast cancer cells to cisplatin.137 HMG 
domain-containing proteins recognize and bind to platinated-DNA, shielding it 
from repair and promoting the binding of p53 to damaged DNA, thus activating 
apoptosis.35 The co-treatment of oestrogen and cisplatin enhances the cytotoxicity 
of cisplatin in ER(+) breast cancer cells by increasing the expression of HMGB1.137 
In view of this, two oestrogen molecules were attached to the axial position of the 
platinum(IV) centre. As expected, treatment of oestrogen-tethered platinum(IV) 
complexes in ER(+) MCF-7 cells increased the expression of HMGB1, due to the 
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release of oestradiol upon the reduction of platinum(IV); this had the desired effect 
of sensitizing the cells to platinum. On the other hand, the expression of HMGB1 
was unaffected in ER(-) HCC-1937 cells and oestrogen-tethered platinum(IV) 
complexes were 2-fold less active in the ER(-) cells.138  
 
Chalcoplatin, a dual-purpose platinum(IV) complex bearing a chalcone moiety, has 
been prepared and evaluated recently in a series of cancer cell lines.139 Chalcone is 
a small molecule that inhibits the MDM2-p53 interaction, where MDM2 interacts 
and degrades p53, inhibiting p53 from sending apoptotic signal to downstream 
effectors.140 The reduction of chalcoplatin releases two molecules of chalcone and 
the cisplatin core. The authors showed that the activity of p53 increased upon 
exposure to chalcoplatin and that higher cytotoxicity was observed in p53-wild type 
cells than in p53-null cells. This application of chalcoplatin demonstrated the 
feasibility of designing platinum(IV) prodrugs that can facilitate the transduction 
of apoptosis signalling after the formation of platinum-DNA adducts.  
 
 
Figure 1.8. Chemical structure of (A) oestrogen-tethered platinum(IV) complexes and (B) 
chalcoplatin. 
Integrins, particularly αVβ3 and αVβ5 integrins, are highly expressed on the tumor 
surface and have been linked to tumor angiogenesis.141 The abundance of integrins 
on tumor cells makes it an attractive target for targeted drug delivery. In view of 
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this, platinum(IV) complexes conjugated axially with integrin-targeting peptides 
have been designed and studied by different groups.142,143 In cells expressing high 
levels of αVβ3 and αVβ5 integrins, the authors noted selective uptake of cellular 
platinum. The activity of these platinum(IV) complexes also correlated with their 
cellular accumulation and expression level of αVβ3 and αVβ5 integrins on the 
cellular membrane.143 The strategy was validated by other groups using different 
targeting peptides.144,145 The success of these integrin-targeted platinum(IV) 
prodrugs demonstrates the possibility of evading drug resistance via the targeted 
delivery and selective uptake of platinum anticancer drugs.   
 
1.4.2 Clinical status of platinum(IV) complexes 
Thus far, four platinum(IV) complexes have been evaluated clinically. Iproplatin 
was the first platinum(IV) complex to enter clinical trials. The platinum(II) 
congener of iproplatin consists of two chlorides and two isopropylamines. It was 
found to be active in numerous in vivo models, and its activity has been attributed 
to the formation of platinum-DNA adducts upon reduction of the platinum(IV) 
species.146 Iproplatin has since been tested in Phase II clinical trials for several 
cancer types, including breast, germ cell carcinomas, testicular, cervical and 
colorectal cancer.147,148,149,150 Yet, iproplatin has been shown to be inactive or less 





Tetraplatin was the second platinum(IV) drug to enter clinical trials in 1994. The 
active platinum(II) species of tetraplatin is similar to that of oxaliplatin, although 
tetraplatin contains both R,R and S,S isomers of the diaminocyclohexane (DACH) 
ligand.151 Tetraplatin was selected for clinical trials because of its superior in vitro 
and in vivo activity against some cisplatin-resistance cancers.152,153 However, 
tetraplatin was only evaluated in Phase I trials, as patients suffered severe 
neurotoxicity attributed to the fast reduction of tetraplatin in the plasma.15  
 
These failures with iproplatin and tetraplatin prompted the search for active, water 
soluble platinum(IV) complexes with better stability in plasma. Ultimately, the 
search led to the discovery of satraplatin, the first orally active platinum drug with 
superior in vivo and in vitro activity against several cisplatin-resistance cell lines.154 
Findings with this compound suggest that DNA repair proteins are unable to 
recognize the DNA lesion caused by satraplatin, and this contributes to the overall 
superior activity of the drug.155,156 Results from Phase I clinical trials suggest that 
satraplatin is also better tolerated than cisplatin and carboplatin. Phase II and III 
clinical trials have been conducted with patients with non-small cell lung cancer, 
head and neck cancer, ovarian cancer and prostate cancer.154 Collectively, 38% to 
62% of patients responded to the treatment and have a better toxicity profile than 
that which would be achieved using cisplatin. Nevertheless, the FDA rejected 
satraplatin, citing that satraplatin did not show any significant improvement on 




LA-12 remains the only platinum(IV) complex currently in clinical trial. LA-12 is 
an analogue of satraplatin, designed such that the cyclohexylamine non-leaving 
group is replaced with adamantylamine.159 LA-12 is reported to be highly cytotoxic, 
with little to no cross-resistance in cisplatin-resistant cell lines.159,160 In xenograft 
mouse models, LA-12 activity was reported to be higher than equimolar doses of 
satraplatin under all concentrations. More encouraging was that the profile of tumor 
remission in A2780 cells after treatment with LA-12 was similar to that of the 
cisplatin-resistant A2780cisR cells, proving the ability of LA-12 to overcome 
cisplatin resistance.161  LA-12 is now in Phase I clinical trials.  
 
 
Figure 1.9. Chemical structure of clinically evaluated platinum(IV) complexes. 
 
1.5 Research objectives and thesis outline 
To date, more than 1000 platinum(IV) complexes have been synthesized and 
evaluated to overcome the shortfalls of the existing clinically evaluated 
platinum(IV) complexes. Yet, because the current optimization strategy focuses 
mainly on improving cytotoxicity, these newly synthesized platinum(IV) 
complexes often fail in vivo or at clinical trials despite showing promising results 
in vitro. Considering this, the main objective of this PhD project is to study the 
Iproplatin Tetraplatin Satraplatin LA-12 
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physical and chemical properties of platinum(IV) complexes that are important and 
relevant for their clinical application.  
 
Cisplatin cytotoxicity is commonly regarded as being related to cellular platinum 
accumulation, and this holds true for platinum (IV) complexes. Thus, it is 
hypothesized that platinum(IV) complexes with improved lipophilicity would 
better accumulate in the cell and, in turn, enhance cytotoxicity. Thus, Chapter 2 
aims to examine the mechanism of cellular uptake of platinum(IV) complexes 
relative to their lipophilicity, and this will be tested in two ovarian cancer cell lines, 
A2780 and cisplatin-resistant A2780cisR. Three asymmetric-platinum(IV) 
complexes (A1, A3 and A4) and one symmetric platinum(IV) bis-benzoate 
complex (PtBz) have been selected to study. The asymmetric-platinum(IV) 
complexes bear acetate and benzoate ligands, and their lipophilicity is tuned by the 
addition of a methyl group to the acetate ligands. PtBz possesses two benzoate 
ligands and it is the most lipophilic complex in the series. To assess how 
platinum(IV) complexes are taken up by the cell, energy-dependency experiments 
will be performed using time- and concentration-dependant uptake assays, as well 
as assays that assess for the effects of temperature, ATP reduction, and the 
inhibition of the Na+, K+-ATPase.   
 
Cisplatin enters the cells and forms platinum-DNA adduct which activates cell 
cycle arrest at G2/M, p53 and DNA repair mechanisms. Failure of the DNA repair 
mechanisms then trigger subsequent signalling pathway for apoptotic cell death.35 
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In the event that lipophilicity improves cell uptake and contributes to cytotoxicity, 
Chapter 3 will examine how the lipophilicity affects cytotoxicity in these prodrugs, 
and how this occurs will be explored as an approach for designing drugs that can 
overcome cisplatin-resistance. The same four platinum(IV) complexes will then be 
tested to further examine the prodrug strategy, and their efficacy will be measured 
using cisplatin as a control. This will be achieved by evaluating how these 
drug/prodrugs affect protein expression associated with p53-dependent apoptosis 
signalling, including p53 and cleaved-PARP. 
 
To further explore the mechanism of uptake of platinum complexes, cellular tracing 
of platinum complex traffic will be performed using elemental analysis, elemental 
imaging, and fluorescence imaging. Cellular tracing of platinum via fluorescence 
imaging is the most popular method, as it is readily accessible and offers real-time 
monitoring.117,118 However, this technique requires a fluorophore be attached to the 
platinum centre, and this can alter the structure and pharmacophore of the 
drug.119,123,124 To resolve this, our group has designed and synthesized a fluorescent 
probe, Rho-DDTC, that can specifically detect platinum(II) complexes.162 It is 
hypothesized that Rho-DDTC can retain its activity and selectively to detect 
platinum(II) species in the cellular environment. Therefore, in Chapter 4, Rho-
DDTC will be used to study the cellular distribution and localization of platinum(II) 




Platinum(IV) complexes with superior in vitro activity may not necessarily 
translate into drugs with good clinical or in vivo efficacy. For example, tetraplatin 
failed at clinical trial because of its fast reduction in the plasma despite its superior 
in vitro and in vivo activity as compared with iproplatin.15 Addressing this 
limitation in tetraplatin led to the discovery of satraplatin, and this highlights the 
importance of fine tuning the physicochemical properties of a drug alongside 
testing its cytotoxic effects.154 The failures of several platinum(IV) candidates 
(such as iproplatin, tetraplatin and satraplatin) are likely attributable to the 
symmetrical nature of the axial ligands, which improved either the efficacy or the 
physicochemical properties of the drug, but not both. To test this hypothesis, our 
group engineered a strategy to install asymmetrical axial ligands that allows for the 
fine-tuning of both the physicochemical and cytotoxic properties of the drug. Thus, 
it is hypothesised here that platinum(IV) complex with balanced physicochemical 
and cytotoxicity properties as a result of the installation of asymmetric ligands will 
exert superior in vivo activity as compared with other drugs. Therefore, Chapter 5 
will explore the importance of physicochemical properties in drug discovery, and 
will select and test a set of prodrugs that show good solubility, permeability, 
stability, rate of reduction and cytotoxicity. These compounds will be analysed as 
orally applicable drugs in an in vivo model of colorectal cancer, and their efficacy 
will be tested against the well-known satraplatin. It is anticipated that these in vivo 
findings will provide clues as to how best to design and optimize clinically 
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Chapter 2  
 




Despite discovering the antitumoral activity of cisplatin in the late 1960s, its 
cellular uptake mechanism is still poorly understood. Early results suggested that 
the cellular uptake of cisplatin, a platinum(II) complex, occurred via passive 
diffusion. Gale and co-workers found that platinum uptake was linear, non-
saturable and only limited by the solubility of the complex.1,2,3,4 Similar results were 
later obtained by other groups in support of these observations. Gale and Andrews 
further proposed the absence of an active transporter, and demonstrated that the 
accumulation of cisplatin was not inhibited by structural analogues or other 
compounds.5,6 Collectively, these findings strongly supported a mechanism of 
passive diffusion for the cellular accumulation of cisplatin. 
 
Despite much effort to show that cisplatin uptake occurs through passive diffusion, 
there is a growing trend indicating that its accumulation in the cell may be also 
facilitated by multiple membrane transporters.7,8 Dornish and co-workers first 
noted that cisplatin levels reduced when cells were incubated with specific protein 
inhibitors (benzaldehyde, pyridoxal, and pyridoxal 5’-phosphate), which suggested 
that the reduction in cisplatin uptake may have been caused by the deactivation of 
active transporters.9,10 Later, it was noted that cisplatin accumulation was reduced 
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by up to 50% when cells were pre-incubated with a Na+, K+-ATPase inhibitor,11 
again suggesting an active route of cisplatin uptake. 
 
Transporters of copper, such as the Copper transporter 1 (CTR1), have also been 
shown to facilitate the uptake of cisplatin.12,13 Deletion or mutation of CTR1 
reduces cisplatin accumulation and increases cellular resistance to the drug.14,15 The 
involvement of CTR1 in the cellular transport of cisplatin suggests a link between 
the cellular mechanisms of copper and platinum. Organic cation transporter (OCT) 
has also been investigated as transporter of platinum drugs. Cisplatin competitively 
inhibits the active uptake of tetraethylammonium (TEA), a substrate of OCT, in 
fibroblastic NIH3T3 cells.16 However, in other cell lines, the role of OCT as a 
cisplatin transporter was not confirmed, and thus there remains some discrepancy 
as to the role of OCT in cisplatin uptake.17  
 
Despite these inconsistencies within the literature regarding cisplatin uptake, 
resistance to cisplatin appears to be directly correlated with its reduced cellular 
accumulation.18,19,20,21 Reduced cellular uptake and increased efflux are the two 
main factors that contribute to the reduced cellular accumulation of cisplatin. With 
this in mind, researchers have designed new cisplatin analogues in an attempt to 
overcome these concerns. One such strategy involves the design of platinum(IV) 
complexes as prodrugs of cisplatin.22 Platinum(IV) prodrugs are structurally 
analogous to cisplatin but with two additional axial ligands that provide a level of 
control over cisplatin cellular uptake.23 Ligands, such as a carboxylate group, 
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increase the lipophilicity of the platinum(IV) complex as compared with cisplatin, 
which is a neutral and hydrophilic. It has been proposed by others that lipophilic 
platinum(IV) complexes will be taken up into cells more readily than cisplatin 
because of their greater passive diffusion across the cellular membrane.24 
 
It is hypothesized that cellular platinum accumulation increases with increased in 
lipophilicity of platinum complexes. Thus, this chapter will explore the relationship 
between lipophilicity and cellular platinum accumulation of platinum(IV) 
(satraplatin, A1, A3, A4 and PtBz) complexes, and contrast that against the 
platinum(II) complexes (cisplatin and oxaliplatin) (Figure 2.1). The asymmetric-
platinum(IV) complexes (A1, A3 and A4) were chosen among the 21 asymmetric-
platinum(IV) complexes designed and synthesized by Dr Chin Chee Fei, where 
their lipophilicity is carefully tuned by the addition of methyl group to the axial 
acetate ligand. Cellular uptake of the platinum complexes is evaluated for their 
energy-dependency through the study of the cellular accumulation under different 
temperature, concentration, incubation time, reduced ATP level and inhibition of 
Na+, K+-ATPase.  
 
Figure 2.1. Chemical structures of platinum(II) (cisplatin and oxaliplatin) and platinum(IV) 
(satraplatin, A1, A3, A4 and PtBz) complexes evaluated for cellular uptake mechanism. 
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2.2 Results and Discussion 
2.2.1 Cellular uptake and nuclear accumulation 
The cellular uptake and distribution of platinum complexes to the nucleus were 
investigated in human ovarian carcinoma A2780 cells and the cisplatin-resistant 
A2780cisR cells. The cells were treated with 1 µM of various platinum drugs for 
24 hours (h), and the platinum content in the whole cell and nuclear compartments 
was determined via ICP-MS (Figure 2.2). The results showed that the cellular 
uptake of platinum complexes increased linearly with an increase in lipophilicity 
(Table S2.1). PtBz—a platinum(IV) complex and the most lipophilic of the drugs 
tested—showed the highest uptake in both cell lines under the same conditions. 
Overall, however, the platinum complexes showed differences in the measured 
cytotoxicities (Table S2.1), which can be explained by the cellular uptake and level 
of nuclear accumulation (Table S2.2 and S2.3). For instance, despite a higher 
absolute platinum accumulation value for complex A1, only 13% of complex A1 
accumulated in the nucleus as compared with 17% for cisplatin. This difference in 
nuclear platinum accumulation contributed to the higher IC50 for complex A1 as 
compared with that for cisplatin in A2780 cells (Table S2.1, S2.2 and S2.3). All 
other platinum complexes with smaller IC50 values in both cell lines showed higher 
nuclear accumulation, with a trend corresponding to an increase in lipophilicity (as 
represented by log Pow). For example, PtBz, which showed the highest cellular and 
nuclear accumulation in both cell lines, had a 50% nuclear accumulation; this high 





Figure 2.2. Whole cell and nuclear accumulation in A2780 (left) and A2780cisR (right) cells after 
drug treatment (1 µM) for 24 h. Refer to Tables S2.2 and S2.3 for actual values.Pt, Platinum.  
 
2.2.2 Time dependence 
The accumulation of platinum complexes in A2780 and A2780cisR cells was 
determined at 37°C over a time frame of 48 h using 1 µM of drug. Generally, 
cellular accumulation of platinum in both cell lines increased with time (Figure 2.3; 
Table S2.4 and S2.5). Cisplatin accumulation in both cell lines reduced from 24 h 
to 48 h. This suggests that the maximum accumulation of the drug is close to 48 h 
and the cells then enter an equilibrium for drug uptake and efflux.  
 
For satraplatin and the other platinum(IV) complexes (A1, A3, A4 and PtBz), 
cellular accumulation continued to increase after 48 h, suggesting that their 
maximum accumulation is much later than that of cisplatin. Besides, the cellular 
uptake of all platinum(IV) complexes was much higher than that of cisplatin. This 
may be explained by the lipophilic nature of the platinum(IV) complexes (Table 
S2.1), as cellular accumulation increased linearly with lipophilicity. The enhanced 
lipophilic nature of the drugs was presumably afforded by the respective axial 
ligands. Thus, it appears that the effective diffusion of lipophilic drugs through the 
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cell membrane leads to a higher and prolonged continual cellular uptake of 
platinum.  
  
Figure 2.3. Cellular accumulation of platinum complexes in A2780 (left) and A2780cisR (right) 
cells at different exposure times. Refer to Tables S2.4 and S2.5 for absolute values. Pt, Platinum 
 
2.2.3 Concentration dependence 
The cellular accumulation of platinum complexes was further tested to determine 
whether a saturated system could be reached. All platinum complexes were tested 
using five concentrations (0.05 µM, 0.10 µM, 0.50 µM, 1.00 µM and 2.00 µM) for 
24 h in both cell lines. A state of “unsaturable” was determined in cases where there 
was a continual increase in cellular accumulation with increasing drug 
concentration. The results showed that none of the platinum complexes tested were 
saturable, as cellular platinum accumulation continued to increase with an increase 
in drug concentration (Figure 2.4; Table S2.6 and S2.7). It is noteworthy that the 
margin of increase for satraplatin and other platinum(IV) complexes (A1, A3, A4 
and PtBz) was much higher compared with that of cisplatin. The unsaturable 
cellular accumulation suggested that the cellular uptake of these platinum 
complexes was not energy dependent; these complexes could continually be taken 




Figure 2.4. Cellular accumulation of platinum complexes in A2780 (left) and A2780cisR (right) 
cells at different platinum drug concentrations. Refer to Table S2.6 and S2.7 for actual values. Pt, 
Platinum 
 
2.2.4 Temperature dependence 
The cellular accumulation of all platinum complexes was evaluated at three 
temperatures. Active transport is an energy-dependent transport, where ATP is 
consumed for the transportation of substrates across the cell membrane. Active 
cellular transport and energy-dependent processes tend to be minimal when cells 
are subjected to temperatures lower than physiological 37°C.25,26,27,28 However, this 
is not the complete picture, as passive diffusion would also be affected by changes 
to cellular temperature,29,30 or membrane fluidity.31,32 Furthermore, the 
rigidification of the cellular membrane at 4°C can greatly affect passive diffusion 
of solutes across the cellular membrane.33  
 
At 4°C, minimal cisplatin was taken up by the cells, which is consistent with the 
proposed nature of passive transport of cisplatin across the membrane (Figure 2.5; 
Table S2.8 and S2.9).1,5 As the temperature increased, so did cisplatin uptake, again 
illustrating the importance of membrane fluidity. The OCT transporter, reported to 
be involved in the uptake of oxaliplatin,34,35 is a secondary active transporter that 
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uses an electrochemical gradient to shunt cations across the cell membrane; i.e., it 
does not function as a result of direct ATP binding.36,36 Hence, rigidification of the 
cell membrane at 4°C likely also affects these membrane transport proteins. 
Additionally, the 4°C temperature would also cause a reduction in energy-
dependent active transport across the cell membrane. Further studies outside the 
scope of this thesis will be needed to deduce the exact energy-dependency of the 
cellular uptake of cisplatin and oxaliplatin. 
 
Among the platinum(IV) complexes studied, PtBz had the highest cellular 
accumulation at all temperatures in both cell lines, and this was followed by 
complex A4, A3, satraplatin and A1 (Figure 2.5; Table S2.8 and S2.9). Cellular 
uptake of PtBz, A4, and A3 even occurred at low temperatures (4°C and 20°C), 
which points to the passive uptake of platinum(IV) complexes. In addition, and as 
seen in earlier experiments, platinum(IV) complex uptake increased proportionally 
with lipophilicity, suggesting that increased lipophilicity improves platinum 
passive uptake in the cell.  This is also relevant at non-physiological temperatures, 
as the cellular platinum(IV) accumulation at 4°C was higher than or similar to that 
of cisplatin and oxaliplatin at 20°C, suggesting that the improved lipophilic nature 





Figure 2.5. Cellular accumulation of platinum complexes in A2780 (left) and A2780cisR (right) 
cells at different incubation temperatures for 3 h. Refer to Table S2.8 and S2.9 for actual values. Pt, 
Platinum 
 
2.2.5 Involvement of ATP in cellular accumulation 
Oligomycin binds to mitochondrial ATP synthase to inhibit oxidative 
phosphorylation and the electron transport chain, and thereby deplete ATP 
resources.37,38 The cellular accumulation of all platinum complexes was evaluated 
with oligomycin co-treatment. The results showed that all platinum(II) and 
platinum(IV) complexes were independent of ATP, with no significant difference 
in platinum accumulation measured as a result of oligomycin co-incubation (Figure 
2.6; Table S2.10). The combined results (of section 2.2.2, 2.2.3 2.2.4 and 2.2.5) 
point towards the energy-independent nature of the uptake of platinum(IV) 
complexes where their uptake are unsaturable, independent of cellular ATP level 
and occurred at low temperature. The findings above correlate with those in the 
literature, where the uptake of cisplatin and oxaliplatin were not saturable, pointing 




Figure 2.6. Cellular accumulation of platinum complexes in A2780 (left) and A2780cisR (right) 
without and co-incubate with 5 µM oligomycin for 3 h at 37°C. Refer to Table S2.10 for actual 
values. Pt, Platinum   
 
2.2.6 Involvement of Na+, K+-ATPase in cellular accumulation 
The Na+, K+-ATPase is a membrane protein responsible for maintaining cell 
potential by regulating the concentration of sodium and potassium ions in the 
cell.11,39 The Na+, K+-ATPase actively pumps sodium ions out of the cells in 
exchange for potassium ions in response to the cellular ionic gradient. Ouabain is a 
specific inhibitor of the Na+, K+-ATPase.40,41 By binding to the Na+, K+-ATPase, 
ouabain inhibits the ATPase activity and causes an increase in cellular sodium 
concentration.  
 
Previous work has shown that inhibiting the Na+, K+-ATPase correlates with a 
decrease in cisplatin uptake.10,9,11 In the resting state, cells are polarized, and the 
membrane potential inside the cell is more negative than that outside. When the 
Na+, K+-ATPase is inhibited, high numbers of Na+ ions accumulate inside the cell 
and activate the Na+/Ca2+ exchanger, which swaps Na+ outside the cell with Ca2+. 
This depolarizes the cell membrane, such that the potential inside the cell becomes 
more positive as compared with the resting potential.42,43 Hence, when the 
membrane is depolarized, less cisplatin can accumulate in the cell. Thus, cisplatin 
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uptake is affected by the membrane potential.8 On the other hand, cisplatin 
accumulation is lower in A2780cisR cells and its uptake is not affected by inhibiting 
the Na+, K+-ATPase. These results correspond to the lower expression of the Na+, 
K+-ATPase α1 subunit found in A2780cisR cells, thus reducing the effect of the 
Na+, K+-ATPase in regulating cisplatin uptake in this cell line.44 Nevertheless, the 
lower accumulation of cisplatin is not responsible for the resistance developed in 
this cell line. Engel and co-workers45 deduced that the platinum resistance in 
A2780cisR is due to an overexpression of AKT, a serine/threonine protein kinase 
that de-sensitizes the cells to cisplatin. As such, a reduction in platinum uptake is 
unlikely to contribute to platinum resistance in A2780cisR, as cisplatin is taken up 
passively into the cells.  
 
In the present study, the co-incubation of ouabain does not affect the cellular 
accumulation of any of the platinum complexes other than cisplatin (Figure 2.7; 
Table S2.10). This suggests that the Na+, K+-ATPase does not play a part in the 
cellular accumulation of oxaliplatin and the platinum(IV) complexes studied. 
However, this cannot rule out the potential involvement of transport-mediated 
proteins in the cellular uptake of oxaliplatin and all platinum(IV) complexes. 
Further studies are needed to exclude the likelihood of facilitated diffusion for 




Figure 2.7. Cellular accumulation of platinum complexes in A2800 (left) and A2780cisR (right) 
cells without and after co-incubation of ouabain (200 nM) for 3 h at 37°C. Refer to Table S2.10 for 
actual values. Pt, Platinum  
 
2.3 Conclusion 
The cellular accumulation of cisplatin in A2780 and A2780cisR cells is passive, 
energy-independent and membrane potential-dependent (in A2780 only). The 
results presented here also suggest that the platinum(IV) complexes are uptake 
passively into the cells via energy-independent pathway, by combining results from 
the low temperature incubation, unsaturable uptake, lack of transporter, and ATP 
depletion. The involvement of energy-dependent pathway in the transportation of 
platinum(IV) complexes has not been completely ruled out but the results here 
suggest that this energy-dependent pathway plays a minimal (and insignificant) role. 
In most cases, the increased lipophilicity afforded by the presence of axial ligands 
on the drugs promoted cellular accumulation, with cellular accumulation increasing 
proportionally with increased lipophilicity. In sum, it is reasonable to suggest that 
increasing the lipophilicity of a platinum(IV) complex to achieve high cellular 






2.4 Experimental Procedures  
2.4.1 Materials 
Chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless 
otherwise stated. Oxaliplatin and satraplatin were purchased from Merlin 
Chemicals Ltd (Liphook, UK). K2PtCl4 was purchased from Furaya Metals (Tokyo, 
Japan). Clinical-grade cisplatin (1 mg/ml) was purchased from Hospira Pty Ltd 
(Melbourne, Australia). Pt(IV) complexes (A1, A3, A4 and PtBz) were prepared as 
described elsewhere.46,47,23,48 Fetal bovine serum (FBS) and RPMI-1640 were 
purchased from Hyclone (Thermo Scientific Inc., Logan, UT, USA). Milli-Q-grade 
purified water was prepared by a Milli-Q UV Purification System (Sartorius Stedim 
Biotech S.A., Aubagne Cedex, France). Thiazolyl blue tetrazolium bromide was 
obtained from Duchefa Biochemie (Haarlem, Netherlands). Nitric acid (65% to 
71%, TraceSELECT Ultra) was obtained from Fluka (Sigma-Aldrich) and used 
without further purification. Platinum and indium standards for ICP-MS 




Concentrations of platinum stock solutions were determined externally by the 
Chemical, Molecular and Materials Analysis Centre (CMMAC, National 
University of Singapore) with Optima ICP-OES (Perkin Elmer, Waltham, MA, 
USA). A synergy H1 hybrid multimode microplate reader (Bio-Tek, Winooski, VT, 
USA) was used to measure UV–Vis absorbance for thiazolyl blue tetrazolium 
bromide (MTT assay) and protein concentrations. Platinum and indium 
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concentrations were determined using an Agilent 7700 Series ICP-MS (Agilent 
Technologies, Santa Clara, CA, USA).  
 
2.4.3 Cell culture  
A2780 human ovarian carcinoma cells and the cisplatin-resistant variant, 
A2780cisR, were cultured in PRMI-1640 supplemented with 10% FBS (complete 
media) at 37°C in a humidified atmosphere of 95% air and 5% CO2.  
 
2.4.4 Cell viability assay (MTT assay) 
Refer Section 3.4.4 
 
2.4.5 Cellular accumulation  
Cellular accumulation of the drugs was measured in A2780 and A2780cisR cells. 
Cells were seeded into 100-mm cell culture dishes at a density of 2.5×106 cells per 
dish and incubated overnight. Drug treatment was performed for varying time 
periods, and the medium containing the platinum complexes was replenished as 
needed. Cells in control wells received RPMI without the drugs. At the end of drug 
incubation, cells were washed three times with 1× PBS. Subsequently, the cells 
were lysed with lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1× protease 
inhibitor, 1% IGEPAL). Cell lysates were centrifuged at 16,000 x g for 20 min. 
Aliquots of the lysates were taken from the main stock for protein determination 
with Bradford reagent. The remaining cell lysate and pellet for each sample were 
then transferred into a glass vial, dried, and then digested with 65% HNO3 at 90°C 
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for 24 h. The resulting solution was diluted to 3% v/v HNO3 using ultrapure water 
containing 1 part per billion (ppb) indium. 
 
2.4.6 Nuclear accumulation experiment 
Cells were treated with 1.00 µM of platinum drugs for 24 h. At the end of drug 
incubation, cells were washed three times with 1× PBS. Subsequently, the cells 
were lysed with lysis buffer (10 mM HEPES pH 7.5, 10 mM KCl, 0.1 mM EDTA, 
1 mM DTT, 0.5% IGEPAL, 1× protease inhibitor). Cell lysates were centrifuged at 
16,000 x g for 20 min. The supernatants were removed and the pellets washed three 
times with lysis buffer. The pelleted nuclei were then lysed in a different lysis buffer 
(20 mM HEPES pH 7.5, 400 mM NaCl, 1 mM EDTA, 25% glycerol, 1 mM DTT, 
1× protease inhibitor). Lysates were centrifuged at 16,000 x g for 20 mins. Aliquots 
of the lysates were taken for protein determination with Bradford reagent. The 
remaining nuclei lysate and pellet for each sample were then transferred into a glass 
vial, dried and digested with 65% HNO3 at 90°C for 24 h. The resulting solution 
was diluted to 3% v/v HNO3 using ultrapure water containing 1 ppb indium. 
 
2.4.7 Time-dependent drug effects 
Cells were treated with 1 µM platinum drugs for 2, 8, 24 or 48 h. 
 
2.4.8 Concentration-dependent drug effects  
Cells were treated with different concentration of platinum drugs for 24 h. The 
concentrations chosen were 0.05 µM, 0.10 µM, 0.50 µM, 1.00 µM and 2.00 µM. 
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2.4.9 Temperature dependence 
Cells were pre-conditioned for 1 h at 4°C, 20°C and 37°C before incubation with 5 
µM of platinum drugs for 3 h.  
 
2.4.10 Involvement of ATP in cellular uptake 
Cells were pre-conditioned with 5 µM oligomycin for 1 h. Cells were then treated 
with 5 µM of platinum drugs containing 5 µM oligomycin for 3 h.  
 
2.4.11 Involvement of Na+/K+ ATPase in cellular uptake 
Cells were pre-conditioned with 200 nM ouabain for 1 h. Cells were then treated 
with 5 µM of platinum drugs containing 200 nM ouabain for 3 h.  
 
2.4.12 ICP-MS analysis 
All samples were analyzed using an Agilent 7700 series ICP-MS. Platinum and 
indium were measured at m/z 195 and m/z 115, respectively. Metal standards were 
freshly prepared before each measurement. Platinum at 0, 0.5, 1, 2, 5, 10, 20, 40 
ppb were used for the calibration curve. All readings were performed in triplicate 
in He mode.  
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2.6 Supplementary Information 





Factorc A2780 A2780 
Cisplatin -2.03 0.91 ± 0.04 9.37 ± 0.25 10.3 
Oxaliplatin -0.47 0.35 ± 0.01 1.26 ± 0.21 3.6 
Satraplatin -0.16 0.65 ± 0.01 1.85 ± 0.06 2.8 
A1 -0.28 1.70 ± 0.17 6.78 ± 0.32 4.0 
A3 0.28 0.34 ± 0.02 1.12 ± 0.17 3.3 
A4 0.46 0.09 ± 0.01 0.34 ± 0.03 3.6 
PtBz 2.19 0.041 ± 0.005 0.24 ± 0.01 5.8 
aLog Pow values were determined with the shake flask method using n-octanol and ultrapure water. 
Data were adapted from a previous study12. bIC50 values are the concentrations of platinum 
complexes required to inhibit 50% of cell growth with respect to control groups, as determined by 
MTT assay after 72 h of incubation. Data represent averages and standard deviations of three 
independent experiments. IC50 values were corrected using actual [Pt] concentration measured by 





Table S2.2. Whole cell and nuclear accumulation in A2780 cells treated with 1 
µM platinum complexes for 24 h at 37°C. 
Complex 
Pt (ng per mg protein) 
Whole cell Nuclear Ratio (%)a 
Cisplatin 8.76 ± 0.37 1.46 ± 0.03 17 
Oxaliplatin 12.21 ± 0.49 4.18 ± 0.16 34 
Satraplatin 18.79 ± 0.78 4.85 ± 0.91 26 
A1 13.57 ± 0.30 1.80 ± 0.22 13 
A3 15.38 ± 0.14 5.25 ± 0.76 34 
A4 17.69 ± 0.08 7.49 ± 0.84 42 
PtBz 49.18 ± 0.30 25.50 ± 0.83 52 
aBased on ratio of Pt[Nuclear] to Pt[Whole cell]. Pt represents concentration of platinum. 
 
Table S2.3. Whole cell and nuclear accumulation in A2780cisR cells treated with 
1 µM platinum complexes for 24 h at 37°C. 
Complex 
Pt (ng per mg protein) 
Whole cell Nuclear Ratio (%)a 
Cisplatin 2.81 ± 0.10 0.36 ± 0.01 13 
Oxaliplatin 6.56 ± 0.32 2.27 ± 0.32 35 
Satraplatin 11.70 ± 0.69 3.17 ± 0.47 27 
A1 6.66 ± 0.38 1.11 ± 0.49 17 
A3 9.40 ± 0.26 3.26 ± 0.49 35 
A4 12.55 ± 0.80 5.15 ± 0.67 41 
PtBz 27.32 ± 1.36 14.02 ± 1.19 51 
aBased on ratio of Pt[Nuclear] to Pt[Whole cell]. Pt represents concentration of platinum. 
 
Table S2.4. Cellular accumulation in A2780 cells treated with 1 µM platinum 
complexes after different incubation times at 37°C. 
Complex 
Pt (ng per mg protein) 
Incubation time (hours) 
2 8 24 48 
Cisplatin 0.89 ± 0.02 2.83 ± 0.04 8.76 ± 0.37 11.86 ± 0.29 
Satraplatin 3.51 ± 0.18 8.65 ± 0.07 18.79 ± 0.78 47.12 ± 0.77 
A1 2.02 ± 0.16 6.28 ± 0.10 13.57 ± 0.30 32.95 ± 1.32 
A3 3.16 ± 0.10 8.51 ± 0.18 15.38 ± 0.14 44.65 ± 0.83 
A4 3.54 ± 0.15 9.31 ± 0.49 17.69 ± 0.08 49.36 ± 2.11 
PtBz 7.16 ± 0.37 17.01 ± 1.05 49.18 ± 0.30 88.42 ± 9.10 
Pt represents concentration of platinum. 
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Table S2.5. Cellular accumulation in A2780cisR cells treated with 1 µM platinum 
complexes after different incubation times at 37°C. 
Complex 
Pt (ng per mg protein) 
Incubation time (hours) 
2 8 24 48 
Cisplatin 0.36 ± 0.02 1.41 ± 0.06 2.81 ± 0.10 3.63 ± 0.07 
Satraplatin 0.90 ± 0.01 4.23 ± 0.13 11.70 ± 0.69 22.57 ± 0.15 
A1 0.44 ± 0.01 2.51 ± 0.04 6.66 ± 0.38 15.63 ± 0.27 
A3 0.64 ± 0.00 3.24 ± 0.02 9.40 ± 0.26 21.70 ± 0.75 
A4 0.92 ± 0.04 4.35 ± 0.06 12.55 ± 0.80 23.35 ± 0.22 
PtBz 2.53 ± 0.15 8.45 ± 0.84 27.32 ± 1.36 41.11 ± 0.27 
Pt represents concentration of platinum. 
 
 
Table S2.6. Cellular accumulation in A2780 cells treated with different 
concentrations of platinum complexes for 24 h at 37°C. 
Complex 
Pt (ng per mg protein) 
Platinum drug concentration (µM) 
0.05 0.10 0.50 1.00 2.00 
Cisplatin 1.18 ± 0.05 1.72 ± 0.07 6.71 ± 0.32 8.76 ± 0.37 14.71 ± 0.32 
Satraplatin 1.55 ± 0.07 2.35 ± 0.05 9.35 ± 0.14 18.79 ± 0.78 28.82 ± 0.68 
A1 1.23 ± 0.13 2.23 ± 0.25 7.21 ± 0.18 13.57 ± 0.30 23.07 ± 0.10 
A3 1.42 ± 0.03 2.28 ± 0.11 8.50 ± 0.21 15.38 ± 0.14 27.88 ± 0.29 
A4 1.46 ± 0.05 2.47 ± 0.04 10.12 ± 0.09 17.69 ± 0.08 27.92 ± 0.14 
PtBz 4.78 ± 0.18 8.20 ± 0.04 25.86 ± 0.14 49.18 ± 0.30 58.79 ± 1.03 
Pt represents concentration of platinum. 
 
Table S2.7. Cellular accumulation in A2780cisR cells treated with different 
concentrations of platinum complexes for 24 h at 37°C. 
Complex 
Pt (ng per mg protein) 
Platinum drug concentration (µM) 
0.05 0.10 0.50 1.00 2.00 
Cisplatin 0.24 ± 0.01 0.35 ± 0.01 1.29 ± 0.04 2.81 ± 0.10 5.32 ± 0.17 
Satraplatin 1.02 ± 0.03 1.61 ± 0.06 6.53 ± 0.35 11.70 ± 0.69 19.56 ± 1.08 
A1 0.76 ± 0.05 1.29 ± 0.06 4.15 ± 0.25 6.66 ± 0.38 12.95 ± 1.02 
A3 0.97 ± 0.05 1.60 ± 0.08 5.94 ± 0.31 9.40 ± 0.26 17.78 ± 1.36 
A4 1.12 ± 0.05 2.39 ± 0.09 6.86 ± 0.56 12.55 ± 0.80 21.17 ± 2.17 
PtBz 2.36 ± 0.02 6.55 ± 0.39 18.28 ± 1.72 27.32 ± 1.36 36.43 ± 1.78 
Pt represents concentration of platinum. 
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Table S2.8. Cellular accumulation in A2780 cells treated with 5 µM platinum 
complexes at different temperatures for 3 h at 37°C. 
Complex 
Pt (ng per mg protein) 
4°C 20°C 37°C 
Cisplatin 0.44 ± 0.05 0.79 ± 0.05 3.05 ± 0.23 
Oxaliplatin 0.57 ± 0.09 0.90 ± 0.08 3.97 ± 0.46 
Satraplatin 0.79 ± 0.05 3.51 ± 0.14 12.66 ± 0.52 
A1 0.69 ± 0.02 1.29 ± 0.07 6.96 ± 0.23 
A3 1.37 ± 0.04 4.77 ± 0.42 13.29 ± 0.69 
A4 2.64 ± 0.09 8.85 ± 0.11 16.44 ± 0.31 
PtBz 4.94 ± 0.17 21.12 ± 0.20 37.68 ± 1.03 
Pt represents concentration of platinum. 
 
Table S2.9. Cellular accumulation in A2780cisR cells treated with 5 µM platinum 
complexes at different temperatures for 3 h at 37°C. 
Complex 
Pt (ng per mg protein) 
4°C 20°C 37°C 
Cisplatin 0.17 ± 0.03 0.34 ± 0.18 0.60 ± 0.05 
Oxaliplatin 0.50 ± 0.02 0.90 ± 0.04 1.22 ± 0.15 
Satraplatin 0.85 ± 0.04 1.97 ± 0.07 8.63 ± 0.82 
A1 0.86 ± 0.05 1.21 ± 0.11 4.30 ± 0.21 
A3 0.96 ± 0.12 2.22 ± 0.15 5.93 ± 0.57 
A4 2.13 ± 0.24 3.35 ± 0.20 8.97 ± 0.46 
PtBz 3.72 ± 0.53 18.63 ± 3.25 27.24 ± 0.81 





Table S2.10. Cellular accumulation in A2780 and A2780cisR cells treated with 5 
µM platinum complexes and co-incubated with 5 µM oligomycin or 200 nM 
ouabain for 3 h at 37°C.   
Complex 
Pt (ng per mg protein) 
A2780 A2780cisR 
Oligomycin Ouabain Oligomycin Ouabain 
Cisplatin 2.75 ± 0.03 1.38 ± 0.18 0.55 ± 0.06 0.56 ± 0.02 
Oxaliplatin 3.33 ± 0.24 3.70 ± 0.27 1.15 ± 0.01 1.03 ± 0.02 
Satraplatin 12.53 ± 0.47 12.84 ± 0.91 8.58 ± 0.30 7.71 ± 0.31 
A1 5.81 ± 0.11 6.22 ± 0.28 3.90 ± 0.71 4.25 ± 0.20 
A3 9.34 ± 0.12 9.23 ± 0.11 5.53 ± 0.15 6.08 ± 0.78 
A4 15.17 ± 1.49 12.27 ± 0.53 8.35 ± 0.21 8.40 ± 0.38 
PtBz 34.75 ± 8.64 38.52 ± 2.79 26.78 ± 0.16 26.35 ± 0.76 









Contrasting anticancer activity of platinum(II) and 
platinum(IV) prodrugs in ovarian cancer cell lines 
 
3.1 Introduction 
Cisplatin is widely used in the treatment of various cancers, including testicular, 
ovarian, lung and bladder cancers. Although the exact mechanism of action of 
cisplatin remains debatable, it is generally accepted that cytotoxicity is caused by 
the formation of platinum (Pt)-DNA adducts in the cell. Upon entry into the cell, 
cisplatin forms two active species, Pt(NH3)2Cl(H2O)
+ and Pt(NH3)2(H2O)2
2+, 
driven by the low intracellular chloride level.1,2 The active species are capable of 
binding to many proteins and nucleic acids in the cell, including DNA, which 
causes the main cytotoxic effect. Cisplatin preferentially binds to the N7 atoms of 
the purine base, forming 1,2-d(GpG) and 1,2-d(ApG) intrastrand cross-links as 
the main products, and 1,3-d(GpXpG) intrastrand and several interstrand cross-
links as minor products.3,4 These Pt-DNA adducts are recognized by several 
proteins, including the DNA mismatch repair protein (hMSH2 and hMSH6), the 
high mobility group box proteins (HMGB1 and HMGB2), upstream-binding 
factor (hUBF), TATA-box-binding protein (TBP) and poly (ADP-ribose) 




p53 is activated following the recognition of DNA damage, and this in turn 
activates subsequent signalling pathways to induce cell cycle arrest, DNA repair 
or apoptosis. p53 activates p21 for cell cycle checkpoint at the G1/S and S/G2 
phases of the cell cycle.8,9,10,11 Cell cycle arrest prevents cells from entering 
mitosis, and provides time for the DNA to be repaired; a failure to repair damaged 
DNA causes caspase activation, which leads to apoptosis.1,8  
 
This chapter sought to further examine the effects of enhanced cellular 
accumulation (due to increased lipophilicity) on the cellular mode of action of the 
lipophilic platinum(IV) complexes (Figure 3.1) evaluated in Chapter 2. 
Cytotoxicity, mode of action and p53 dependence of the platinum(IV) complexes 
will be evaluated in cancer cell lines, and correlate to their lipophilicity to 
examine the strategy of designing lipophilic platinum(IV) complexes. Results 
obtained will also be compared with those of cisplatin, the parental drug, to verify 
that these platinum(IV) complexes function similarly to that of cisplatin.  
 
 
Figure 3.1. Chemical structures of cisplatin and platinum(IV) complexes. 
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3.2 Results and Discussion 
3.2.1 Cytotoxicity studies and cellular accumulation 
Cytotoxicity of all platinum complexes was evaluated using two human ovarian 
cancer cell lines (Table S2.1). The platinum(IV) complexes (satraplatin, A1, A3, 
A4, PtBz) showed comparable or better efficacies as compared with that of 
cisplatin in the two cell lines evaluated. Cross-resistance toward the cisplatin-
resistant A2780cisR was still observed for all platinum(IV) complexes with 
resistance factors between 2.8 to 5.8; these values are still better than that of 
cisplatin (resistance factor, 10.3). These increases in cytotoxicity could be due to 
the increase in lipophilicity owing to the presence of the lipophilic ligands on the 
platinum(IV) complexes (Figure 2.2; Table S2.2 and S2.3). The increase in 
lipophilicity allows an increase in cellular uptake and nuclear accumulation, 
thereby killing the cancer cells more effectively. Furthermore, all platinum(IV) 
complexes showed a lower ratio in their whole cell and nuclear accumulation 
between A2780 and the cisplatin-resistant A2780cisR cells, compared to that of 
cisplatin (Table S3.1). The lower resistance factor and smaller magnitude of 
reduction in cellular accumulation in platinum(IV) treated A2780cisR cells enable 
these platinum(IV) complexes to overcome cisplatin resistant.  
 
3.2.2 p53 dependence and apoptosis 
Cisplatin induces DNA damage, and its action is recognized by the p53 tumor 
suppressor protein to trigger cell cycle arrest.10,12 Failure to repair DNA damage 
will also prompt p53 to initiate apoptotic cell death.13 The dependency on p53 for 
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platinum complex-induced cell death was examined in four cells lines: two human 
ovarian cancer cell lines (A2780 and A2780cisR), with the use of pifithrin-α 
(PFT-α), a p53 inhibitor (Figure 3.2 and S3.1; Table 3.1); and in the paired human 
colorectal carcinoma cell lines (HCT116 WT and HCT116 p53-/-; Figure 3.3 and 
S3.2), the latter deficient in p53.   
 




- + - + 
Cisplatin 0.91 ± 0.04 2.92 ± 0.34 9.37 ± 0.25 34.70 ± 0.80 
Satraplatin 0.65 ± 0.01 0.81 ± 0.05 1.85 ± 0.06 3.00 ± 0.42 
A1 1.70 ± 0.17 1.64 ± 0.08 6.78 ± 0.32 6.17 ± 0.66 
A3 0.34 ± 0.02 0.34 ± 0.00 1.12 ± 0.17 0.95 ± 0.05 
A4 0.09 ± 0.01 0.09 ± 0.01 0.34 ± 0.03 0.31 ± 0.04 
PtBz 0.041 ± 0.005 0.040 ± 0.007 0.24 ± 0.01 0.22 ± 0.02 
IC50 values are the concentrations of platinum complexes required to inhibit 50% of cell growth 
with respect to control groups, as determined by MTT assay after 72 h of incubation. Data 
represent averages and standard deviations of three independent experiments. IC50 values were 
corrected using actual [Pt] concentrations measured by ICP-OES.  
 
 
Figure 3.2. IC50 values of platinum drugs evaluated in human ovarian cancer cell lines. Data 
represent mean ± SEM of three independent experiments. Statistical analysis was done with two-
tailed Student’s t-test (**p<0.01, ***p<0.001). 
 
As expected, the activity of cisplatin is p53-dependent in the two ovarian cancer 
cell lines, where its cytotoxicity increases proportional to a decrease in the 
activity of p53 with pifithrin-α treatment. On the other hand, platinum(IV) 
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complexes (A1, A3, A4 and PtBz) were p53-independent, as their cytotoxicities 
did not change upon co-incubation with pifithrin-α. The activity of satraplatin was 
affected minimally, with a 1.25× and 1.62× increase in the IC50 of satraplatin 
upon co-incubation with pifithrin-α in A2780 and A2780cisR cell lines. Hence, 
the activity of satraplatin in ovarian cancer cell lines were determined to be also 
p53-independent. Similarly, for the human CRC cell lines, cisplatin acted in a 
p53-dependent manner, while satraplatin and the other platinum(IV) complexes 
(A1, A3, A4 and PtBz) appeared to be p53-independent. These results further 
support the assumption that the platinum(IV) complexes (A1, A3, A4 and PtBz) 
are p53-independent.  
 
Figure 3.3. aIC50 values are the concentrations of platinum complexes required to inhibit 50% of 
cell growth with respect to control groups, as determined by MTT assay after 72 h of incubation. 
Data represent averages and standard deviations of three independent experiments. IC50 values 
were corrected using actual [Pt] concentrations measured by ICP-OES. Data represent mean ± 
SEM of three independent experiments. Statistical analysis was done with a two-tailed Student’s t-
test (**p<0.01, ***p<0.001). 
 
 IC50 [µM]a  
 
Complex HCT116 WT HCT116 p53-/- 
Cisplatin 3.40 ± 0.13 10.56 ± 0.46 
Satraplatin 1.90 ± 0.04 2.25 ± 0.23 
A1 9.37 ± 1.02 9.57 ± 0.55 
A3 1.82 ± 0.14 1.84 ± 0.09 
A4 0.70 ± 0.08 0.82 ± 0.08 
PtBz 0.24 ± 0.02 0.21 ± 0.01 
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Figure 3.4. Western blotting for the detection of p53 and cleaved-PARP expression in A2780 
cells treated with platinum complexes for different exposure times (6, 24, 48 and 72 hours). Actin 
was used as a reference for homogenous protein loading. 
 
Figure 3.5. Western blotting for the detection of p53 and cleaved-PARP expression in A2780cisR 
cells treated with platinum complexes for different exposure times (6, 24, 48 and 72 hours). Actin 
was used as a reference for homogenous protein loading. 
 
To further confirm the results, western blotting was employed to measure the 
protein expression of p53 (Figures 3.4 and 3.5). In line with the findings above, 
p53 expression increased over the 72-h treatment for cisplatin and satraplatin, as 
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did its expression following treatment with complex A1 and A3; albeit, not as 
strongly. As for A4 and PtBz, p53 expression remained unchanged at basal levels, 
regardless of the duration of the treatment or the concentration of the drug. 
Results from cell viability study simply indicate that platinum(IV) complexes 
(satraplatin, A1, A3, A4 and PtBz) were p53-independent. Measurement of p53 
expression further revealed that such dependency is correlate to their lipophilicity. 
Satraplatin and A1 are the least lipophilic among the platinum(IV) complexes and 
showed activation of p53 but not as strong as that of cisplatin. The level of 
activated p53 decrease further in cells treated with A3 while no observable 
activation of p53 can be seen in cells treated with A4 and PtBz (most lipophilic 
compound in the series). This p53-independent apoptosis by platinum(IV) 
complexes may be an effect of the high cellular accumulation of these drugs (due 
to increased lipophilicity).  
 
Cleaved-PARP serves as an indicator of apoptosis.14,15 The results in the present 
chapter show that all platinum complexes induced apoptotic cell death at 72 h in 
A2780 and A2780cisR cells (Figures 3.4 and 3.5). It is noteworthy that 
platinum(IV) complexes A4 and PtBz induced apoptosis later than the other 
platinum complexes. The p53-independent apoptotic cell death in response to 
treatment with platinum(IV) complexes (satraplatin, A1, A3, A4 and PtBz) may 
be mediated by p73, a p53 homologue.16,17,18 p73 can induce apoptosis in cells 
following cisplatin treatment,19,20 and this is thought to be regulated by c-Abl 
kinase and the mismatch repair protein, MutL Homolog 1 (MLH1).21,22,23 p73 is 
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also able to activate p21, which triggers cell cycle arrest and apoptosis in a similar 
fashion as does p53.24,25,17 
 
Platinum(IV) complexes were further investigated for their ability to induce 
apoptosis in a manner similar to that of cisplatin through the Annexin-V assay 
(Figures 3.6, 3.7, S3.3 and S3.4). As expected, cisplatin induced apoptosis in both 
cell lines, with the number of apoptotic cells increasing with an increase in the 
drug concentration. Similarly, platinum(IV) complexes (satraplatin, A1, A3, A4 
and PtBz) induced apoptosis in both cell lines in a concentration-dependent 
manner. These results suggest that the platinum(IV) complexes studied may be 
prodrugs of cisplatin, as they display similar functionality to that of cisplatin in 
inducing apoptotic cell death. 
 
Figure 3.6. Annexin-V assay of platinum complexes on A2780 human ovarian cancer cells. Cells 
were treated with platinum complexes at 1×, 2× and 5× of their IC50 values for 72 h. Cells were 




Figure 3.7. Annexin-V assay of platinum complexes on A2780cisR human ovarian cancer cells 
with cisplatin resistance. Cells were treated with platinum complexes at 1×, 2× and 5× of their 
IC50 values for 72 h. Cells were stained with Annexin-V FITC and propidium iodide prior to 
analysis by flow cytometry.  
 
3.2.3 Cell cycle analysis 
To further understand how platinum(IV) complexes induce their effect, cell cycle 
analysis was performed using the two ovarian cancer cell lines. The results 
showed that DNA damage induced by cisplatin was sensed at 24 h, triggering an 
arrest in the cell cycle at the G2/M phase (Figures 3.8 and 3.9). After 72 h, an 
even higher proportion of cells accumulated in the G2/M phase, which resulted in 
cell death. Similarly, all platinum(IV) complexes showed an increased proportion 
of cells in the G2/M phase between 24–72 h. These findings suggest that all 
platinum(IV) complexes (satraplatin, A1, A3, A4 and PtBz) studied in this 
experiment behave in a manner similar to cisplatin, inducing DNA damage and 
cell cycle arrest at the G2/M phase, and, presumably, causing a failure in DNA 





Figure 3.8. Cell cycle distribution of A2780 cells treated with platinum(IV) complexes at 
individual IC50 values for 24 (orange), 48 (blue), and 72 (red) h.  
 
Figure 3.9. Cell cycle distribution of A2780cisR cells treated with platinum(IV) complexes at 






Overall, the platinum(IV) complexes satraplatin, A1, A3, A4 and PtBz induced 
apoptotic cell death and cell cycle arrest similar to that of cisplatin. Cytotoxicity 
of platinum(IV) complexes increase with increased in lipophilicity which can be 
well explained by their enhanced cellular accumulation. However, the activity of 
the platinum(IV) complexes appeared to be independent of p53: the high cellular 
platinum accumulation as a result of increased lipophilicity, caused a shift toward 
p53 independency in signalling for apoptotic cell death. From these findings, it is 
clear that further investigations are warranted as to the exact mechanism of action 
of platinum(IV) complexes. Nevertheless, these results support the development 
of new platinum complexes with high cellular accumulation as a means to 
overcome drug resistance.  
 
3.4 Experimental Procedures 
3.4.1 Materials 
Chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA) unless 
otherwise stated. Satraplatin was purchased from Merlin Chemicals LTD 
(Liphook, UK). K2PtCl4 was purchased from Furaya Metals (Tokyo, Japan). 
Clinical-grade cisplatin (1 mg/ml) was purchased from Hospira Pty Ltd 
(Melbourne, Australia). Pt(IV) complexes (A1, A3, A4 and PtBz) were prepared 
as described elsewhere.26 Thiazolyl blue tetrazolium bromide and pifithrin-α 
(PFT-α) were purchased from Tokyo Chemical Industry (Tokyo, Japan). Foetal 
bovine serum (FBS), Trypsin, RPMI-1640 and DMEM medium were from 
Hyclone (Thermo Scientific Inc., Logan, UT, USA). Milli-Q-grade purified water 
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was prepared by a Milli-Q UV Purification System (Sartorius Stedim Biotech 
S.A., Aubagne Cedex, France). Antibodies p53 (FL-393) was purchased from 
Santa Cruz Biotechnology (Dallas, TX, USA). Cleaved-PARP (Asp214) and anti-
rabbit IgG (7074) were purchased from Cell Signaling Technology (Danvers, MA, 
USA). β-actin was purchased from Abcam (Cambridge, MA, USA). Luminata 
Classico, Luminata Crescendo and Luminata Forte Western HRP Substrate were 
purchased from Merck Millipore Corporation (Darmstadt, Germany). Quick Start 
Bradford 1× Dye Reagent, 30% Acrylamide/Bis solution, 0.2 µm nitrocellulose 
paper and filter paper were purchased from Bio-Rad Laboratories (Hercules, CA, 
USA). Thiazolyl blue tetrazolium bromide (MTT) was obtained from Duchefa 
Biochemie (Haarlem, Netherlands). Nitric acid (65% to 71%, TraceSELECT 
Ultra) as obtained from Fluka (Sigma-Aldrich) and used without further 
purification. Platinum and indium standards for ICP-MS measurements were 
obtained from CPI International (Amsterdam, The Netherlands). 
 
3.4.2 Instrumentation 
Concentrations of platinum stock solutions were determined externally by 
Chemical, Molecular and Materials Analysis Centre (CMMAC (National 
University of Singapore) with Optima ICP-OES (Perkin Elmer, Waltham, MA, 
USA). A synergy H1 hybrid multimode microplate reader (Bio-Tek, Winooski, 
VT, USA) was used to measure UV–Vis absorbance for MTT and protein 
concentrations. Flow cytometry was performed on BD LSRFortessa Cell 
Analyzer (BD Biosciences, Franklin Lakes, NJ, USA). Western blot images were 
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generated on a G:Box (Syngene, Cambridge, UK). Platinum and indium 
concentrations in cells were determined using an Agilent 7700 Series ICP-MS 
(Agilent Technologies, Santa Clara, CA, USA).. 
 
3.4.3 Cell culture  
A2780 human ovarian carcinoma cells and the cisplatin-resistant variant 
A2780cisR cells were cultured in RPMI-1640 supplemented with 10% FBS at 
37°C in a humidified atmosphere of 95% air and 5% CO2. 1 µM cisplatin was 
added to the media of A2780cisR cells every 3 passages to maintain their 
resistance. HCT116 WT and HCT116 p53-/- human colon cancer cells were 
cultured in DMEM supplemented with 10% FBS at 37°C in a humidified 
atmosphere of 95% air and 5% CO2.  
 
3.4.4 Cell viability assay (MTT assay) 
A2780, A2780cisR, HCT116 WT and HCT116 p53-/- cells were seeded at 
densities of 6000, 6000, 2500, and 2500 cells, respectively, into the wells of 96-
well plates and incubated for 24 hours (h). Stock solutions of drugs were prepared 
as follows: cisplatin was prepared in 0.9% NaCl; satraplatin was prepared in 
ultrapure water; and all other platinum(IV) drugs were prepared in DMSO. All 
cells were exposed to 1% v/v DMSO. Cells were exposed to drugs at different 
concentrations in RPMI-1640 (A2780 and A2780cisR) or DMEM (HCT116 WT 
and HCT116 p53-/-) for 72 h. After 72 h, the medium was replaced with MTT 
solution (0.5 mg/mL in 1× PBS) and incubated for 1 h. The medium was aspirated 
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and DMSO was added to dissolve the purple formazan crystal that had formed. 
Cell viability was determined by measuring the absorbance at 570 nm. Three 
independent experiments were carried out using six repeats for each concentration. 
Cytotoxicity was determined based on the IC50 value (50% reduction in the viable 
cells as compared with the untreated control). 
 
3.4.5 Cellular accumulation experiment 
Refer Section 2.4.5 Cellular accumulation  
 
3.4.6 Nuclear accumulation experiment 
Refer Section 2.4.6 Nuclear accumulation experiment  
 
3.4.7 ICP-MS analysis 
Refer Section 2.4.12 ICP-MS analysis 
 
3.4.8 Annexin-V assay 
A2780 and A2780cisR cells were seeded at 6 × 104 cells per well of a 12-well 
plate and incubated overnight. Cells were then treated with various concentrations 
of platinum drugs for 72 h. The drug-containing media was then collected and the 
cells were trypsinized and combined with the previously collected drug-
containing media. Cells were washed once in 1× PBS. Cells were counted, and 1 
× 105 cells were suspended in 100 µL of Annexin-V binding buffer (10 mM 
HEPES (pH 7.4), 140 mM NaCl, 2.5 mM CaCl2, 1 mM MgCl2) containing 1 × 
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Annexin-V FITC and propidium iodide (PI; 1 µg/mL). Cells were mixed and 
incubated for 15 min at room temperature in the dark. The samples were then 
mixed with 400 µL of binding buffer and analysed immediately using a flow 




Approximately 5 × 105 cells were seeded into each well of a 6-well plate and 
incubated overnight. Cells were then treated with various concentrations of 
platinum drugs for 6, 24, 48 or 72 h. Cells were washed three times with 1× PBS 
and then lysed in 100 µL of cold lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 
1× protease and phosphatase inhibitor, 1% IGEPAL). Cells were collected using a 
cell scraper and centrifuged at 16,000 x g for 20 min at 4°C. A Bradford assay 
was used to quantify the protein concentration of each sample. Samples (50 µg) 
were then reconstituted in loading buffer (5% DTT, 1× Protein Loading Dye) and 
heated at 95°C for 5 min. Proteins were loaded and resolved on a 10% SDS-
polyacrylamide gel and transferred onto nitrocellulose membranes. Membranes 
were blocked with blocking buffer (5% bovine serum albumin (BSA) dissolved in 
1× TBS with 0.1% Tween-20) for 1 h at room temperature. Primary antibodies 
were diluted in blocking buffer overnight at 4oC. Membranes were washed three 
times with wash buffer (1× TBS, 0.1% Tween-20) and then incubated with 
secondary antibodies (diluted in blocking buffer) for 1 h at room temperature. 
Membranes were then washed three times with wash buffer and treated with 
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Luminata Crescendo Western HRP substrate (Merck Millipore). Imaging was 
performed with a G:Box. All antibodies were used at 1:1000 dilutions, except for 
β-actin (1:10000) and anti-rabbit IgG (1:5000). The experiment was performed 
thrice independently. 
 
3.4.10 Cell cycle analysis 
A2780 and A2780cisR cells were seeded at 6 × 104 cells per well into the wells of 
a 12-well plate and incubated overnight. Cells were then treated with 1 mM of 
thymidine for 16 h, washed three times with 1× PBS, and then incubated in RPMI 
media for 9 h. Cells were then treated with 1 mM of thymidine for an additional 
16 h, washed, and then treated with platinum drugs at different concentrations for 
24, 48 and 72 h. At each time point, cells were harvested by trypsinization, 
washed twice in 1× PBS, and then fixed with 70% ethanol for 2 h on ice. After 
fixing, cells were washed twice with 1× PBS, and then suspended in 500 µL of 1× 
PBS containing 0.1% Triton X-100, 0.2 mg/mL RNase A, 20 µg/mL PI. Cells 
were incubated for 1 h at room temperature before analysis with a flow cytometer 
(BD LSRFortessa). Images were processed using FlowJo (version 7.6.1). The 
experiment was performed twice independently. 
 
3.4.11 Statistical Analysis 
Statistical analysis was performed using an unpaired Student’s t test with 
GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA). p<0.05 was 
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Figure S3.1. (a) Representative dose response curves of A2780 cells treated with 
platinum drugs only (black) or platinum drugs with pifithrin-alpha (red), as 
determined by MTT after 72 h. (b) Representative dose response curves of 
A2780cisR cells treated with platinum drugs only (black) and platinum drugs with 





Figure S3.2. Representative dose response curves of platinum drugs in 
HCT116WT (black) and HCT116 p53-/- (red) cells, as determined by MTT assay 







Figure S3.3. Annexin-V assay of platinum complexes on A2780 cells. Cells were 
treated with platinum complexes at 1×, 2× and 5 × their respective IC50 values for 
72 h. Cells were stained with Annexin-V FITC and propidium iodide prior to 










Figure S3.4. Annexin-V assay of platinum complexes on A2780cisR cells. Cells 
were treated with platinum complexes at 1×, 2× and 5× their respective IC50 
values for 72 h. Cells were stained with Annexin-V FITC and propidium iodide 
prior to analysis by flow cytometry. 
 
Table S3.1. Ratio of whole cell and nuclear platinum accumulation in A2780 and 
A2780cisR. 
Complex 
Ratio of whole cell platinum 
accumulation  
Pt[A2780] / Pt[A2780cisR]a 
Ratio of nuclear platinum 
accumulation  
Pt[A2780] / Pt[A2780cisR]a 
Cisplatin 3.1 4.1 
Satraplatin 1.6 1.5 
A1 2.0 1.6 
A3 1.6 1.6 
A4 1.4 1.5 
PtBz 1.8 1.8 
aRefer to Table S2.2 and S2.3 for platinum concentration in each cell line.  
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Chapter 4  
Visualization of cellular uptake of platinum drugs with 
 fluorescence imaging 
 
4.1 Introduction 
Cisplatin is one of the most important anticancer drugs used in the clinic. However, 
the application of cisplatin has been limited by its severe side effects, toxicity and 
the development of resistance to the drug.1 Using a prodrug strategy, a new series 
of platinum(IV)-based anticancer drugs have been developed to overcome the 
limitations faced by cisplatin.2  
 
Platinum(IV) prodrugs are structurally analogous to cisplatin but with two 
additional axial ligands.3,4 Platinum(IV) prodrugs are not known to be active but 
have to be reduced to their active drug form (i.e., their platinum(II) centre, e.g., 
cisplatin) in order to exhibit a cytotoxic effect.5 Prodrugs can be reduced by 
biological reducing agents, such as haemoglobin, methionine, cysteine, glutathione, 
and ascorbic acid.6,7 Satraplatin, a platinum(IV) drug, can be reduced by 
haemoglobin or cytochrome c with NADH.6 Although much work has sought to 
address the mechanism of action of platinum(II) drugs and platinum(IV) prodrugs, 
the mechanisms of cellular uptake and the reduction of these platinum drugs 
remains unclear. An understanding of these pathways could help to clarify how 




Cellular imaging techniques with fluorescence microscopy are the most popular, 
effective and accessible techniques for detecting and monitoring platinum in live 
cells via attachment of a fluorophore to the drug.8,9 However, these bulky 
fluorophores can alter drug uptake characteristics, pharmacokinetics and 
pharmacodynamics, rendering them different from cisplatin. Furthermore, it is 
possible that displacement of the fluorophore may provide misleading information 
as to the location of the drug.8,10  
 
An ideal imaging probe should be independent from the platinum scaffold and yet 
able to selectively identify platinum(II) and/or platinum(IV) within the cellular 
environment. A recognition motif coupled to the probe could be used to recognize 
and react specifically with the platinum species rather than other biological metals. 
Further, the probe could be tuned to react specifically with platinum(II) drugs rather 
than platinum(IV) prodrugs, as platinum(IV) prodrugs are less reactive than 
platinum(II) products.  
 
As a proof-of-concept, a fluorescent probe that would specifically detect 
platinum(II) drugs in the cellular environment was designed and synthesized by Dr 
Diego Montagner.11 The fluorescent probe, Rho-DDTC, was designed by tethering 
the non-fluorescence spirolactam form of rhodamine B (RhoB) to a recognition 
motif consisting of diethyldithiocarbamate (DDTC) (Figure 4.1).11 DDTC was 
chosen because of its strong affinity toward platinum(II) complexes. Besides, 
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sodium DDTC has been clinically evaluated for its ability to seize excess 
administered cisplatin,12,13 and in the quantification of cisplatin and cis-
diammineaqua-chloroplatinum(II) ions in human blood plasma.14,15,16 DDTC binds 
to platinum(II) via a dithiocarbonyl bond, and a trans-effect causes the labilization 
of the ligand, which then reacts with the spirolactam motif of Rho-DDTC to turn 
on the fluorescence. Rho-DDTC is stable at physiological pH and selective towards 
platinum(II) and cisplatin as compared with other biologically relevant metals. 
Moreover, Rho-DDTC reacts specifically with platinum(II), recognizes different 
platinum(II) scaffolds and remains inert towards platinum(IV) complexes (Figure 
S4.11; Table S4.1).11  
 
The activity of Rho-DDTC in a complex cellular environment, however, is 
unknown. The activity of a fluorescent probe may be hindered in a cellular 
environment due to the complexity of the cell and potential interference from 
biomolecules. Such interference may induce non-specific turn-on fluorescence or 
quench the fluorescence output. Therefore, this chapter sought to examine the 
applicability of Rho-DDTC as a cellular probe to study the fate of platinum(II) and 
platinum(IV) complexes in cells. 
 
 
Figure 4.1. Fluorescence probe, Rho-DDTC (diethyldithiocarbamate). Refer to supplementary 
information for synthesis and characterization of Rho-DDTC by Dr Diego Montagner (Figure S4.1 
– Figure S4.12; Table S4.1). 
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4.2 Results and Discussion 
4.2.1 Selectivity of Rho-DDTC against cisplatin in the cellular environment 
To evaluate the performance of Rho-DDTC in the cellular environment, HeLa cells 
were exposed to different concentrations of cisplatin, from 0.5× to 10× of its IC50 
value (3 µM), for 3 h. Cells were then treated with Rho-DDTC, fixed with 4% 
paraformaldehyde, stained with Hoechst 33342 nuclear dye and viewed under a 
laser scanning confocal microscope (Figure 4.2 and S4.13). Internalization of 
cisplatin into the cells was clearly observed from 2× to 10× the IC50 of cisplatin, 
with fluorescence dispersed within the cytoplasm. However, no fluorescence co-
localized with the Hoechst 33342 nuclear dye, indicating an absence of nuclear 
localization. This could be due to a few reasons: (1) Rho-DDTC may be unable to 
penetrate the nuclear membrane; (2) the platinum level in the nucleus may be 
beneath the threshold fluorescence intensity; or (3) Rho-DDTC is only able to 
recognize free cisplatin and unable to react with platinated biomolecules. 
 
Figure 4.2. Fluorescence imaging of HeLa cells treated with cisplatin at different concentrations 
for 3 h and further incubated with Rho-DDTC (30 µM) for 1 h at 37°C, fixed with 4% 





4.2.2 Reactivity of Rho-DDTC with platinated biomolecules 
An absence of fluorescence from the nucleus prompted the study of reactivity of 
Rho-DDTC with platinated biomolecules. A platinated plasmid was prepared by 
treating plasmid pET 23/42 with various concentrations of cisplatin. Reactions of 
Rho-DDTC with platinated plasmid samples was measured at a fluorescence 
intensity at 585 nm (λex 490 nm) (Figure 4.3). 
  
Figure 4.3. Fluorescence intensity measurements. Cisplatin (cDDP) at different concentrations (0.8, 
1.6, 3.1, 6.2, 12.5, 25.0, 50.0 µM) and platinated pET 23/42 (50, 100, 200, 300 µM) was reacted 
with Rho-DDTC (50 µM) for 24 h at 50°C. Data are from three independent experiments. The 
calculated SD is much smaller than the symbol used for data points and results in no observable 
error bar on the data points. 
 
No fluorescence was observed from the platinated plasmid samples when treated 
with Rho-DDTC. This suggests that Rho-DDTC is unable to recognize platinated 
DNA and turn on fluorescence. Rho-DDTC recognizes cisplatin and turns on 
fluorescence by replacing the two chlorides and one amine ligand on the cisplatin 
molecule with sulphur atoms (of DDTC motif) and an oxygen atom (of spirolactam 
motif). However, the bond formed between the platinum centre and the nitrogen on 
DNA bases such as guanosine and adenosine (Pt-N) is much stronger than the bond 
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formed with the chloride ions (Pt-Cl). Hence, the absence of fluorescence turn-on 
for Rho-DDTC suggests that Rho-DDTC is unable to replace the ligands of 
platinated-DNA. 
 
4.2.3 Selectivity of Rho-DDTC for specific platinum(II) scaffold 
Fluorescence was further investigated using platinum(II) scaffolds (cisplatin, 
JM118, oxaliplatin; Figure 4.4) to show selectivity of binding. Cells treated with 
cisplatin and JM118 (the major metabolite of satraplatin) exhibited fluorescence, 
whereas cells treated with oxaliplatin, a platinum(II) drug, did not show 
fluorescence turn-on (Figure 4.5). This further confirms that Rho-DDTC 
specifically recognizes the [cis-Pt(Am)2X2] scaffold (Table S4.1) and that 
fluorescence turn-on is specific and is not induced from non-specific interactions 
within the cellular environment. 
 
Fluorescence turn-on was also observed in cells treated with platinum(IV) 
complexes (PtIV(OH)2, PtBz and satraplatin; Figure 4.4) after 3 h of treatment. 
Because Rho-DDTC binds specifically to platinum(II), the results suggest that the 
reduction of platinum(IV) to platinum(II) is fast. The fluorescence in cells treated 
with PtIV(OH)2 and PtBz are found within the cytoplasm, similar to that observed 
in the cisplatin-treated sample (Figure 4.5 and S4.14). However, the fluorescence 
intensity of PtBz is more intense than PtIV(OH)2 and the compound concentrates 
around the nucleus (Figure 4.5 and S4.14). This could due to the lipophilic nature 
of the two aromatic carboxylate axial ligands of PtBz, which enable it to diffuse 
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easily into the cells. The result correlates well with the cytotoxicity of the two 
complexes, as PtBz is more cytotoxic than PtIV(OH)2. 
 
The probe was also tested against the platinum(IV) drug candidate satraplatin and 
its metabolite JM118 (Figure 4.4). Satraplatin is more lipophilic than JM118 due to 
the two acetate axial ligands and this allowed more satraplatin to be taken up into 
the cells. Hence, cells treated with satraplatin exhibited stronger fluorescence 
intensity than those treated with JM118 (Figure 4.5 and S4.14).  
 




Figure 4.5. Fluorescence imaging of HeLa cells treated with different platinum complexes (30 µM) 
for 3 h and further incubated with Rho-DDTC (30 µM) for 1 h at 37°C. Cells were fixed with 4% 





4.2.4 Probing cellular localization of platinum complexes with Rho-DDTC 
Immunostaining with organelle antibodies was performed to determine the 
localization of PtBz in the cell. Six markers for organelles were used, including 
endosome (EEA1), endoplasmic reticulum (PDI), golgi (RCAS1), lysosome 
(LAMP1), mitochondria (AIF), and nuclear envelope (NUP98). The results suggest 
that PtBz localized in the endoplasmic reticulum rather than within the nuclear 
envelope (Figure 4.6 and S4.15; Table S4.2).  
 
PtBz is 22 times more cytotoxic than cisplatin. The superior cytotoxicity of PtBz is 
attributed to the higher platinum accumulation in the nucleus and its DNA binding 
activity. In Chapter 2, the cellular uptake studies of PtBz showed that about 50% 
of total cellular platinum was found in the nucleus and that the absolute platinum 
content was 17 times higher for PtBz than cisplatin. In addition, the results from 
Chapter 3 suggested that PtBz and cisplatin shared a similar mode of action in 
triggering apoptosis. Nevertheless, immunoblotting with CHOP protein—a protein 
induced by ER stress—was carried out to check for a secondary mechanism of PtBz 
action that is different to that of cisplatin (Figure S4.16). Indeed, PtBz does not 
induce ER stress (same as cisplatin) and the expression of CHOP was similar to 
that of the untreated control. Hence, the localization in ER could be explained as 
follows: Rho-DDTC captures the reduced platinum(II) species of PtBz while it is 




Figure 4.6. Fluorescence imaging of Ishikawa cells treated with PtBz (30µM) for 3 h, fixed with 4% 
paraformaldehyde, stained with antibody and further incubated with Rho-DDTC (30 µM) for 1 h at 







Rho-DDTC was designed to study the fate of platinum in cells. Rho-DDTC is 
compatible with the cellular environment and its activity is specific toward 
platinum(II) complexes. However, the inability of Rho-DDTC to turn-on in the 
presence of platinated DNA impedes its use in the study of biomolecule-bounded 
platinum species. Hence, Rho-DDTC can only be used to study the fate of free 
cisplatin or platinum(II) before it binds to biomolecules. Despite this limitation, the 
probe can identify cisplatin internalization, with fluorescence observed between 2× 
to 10× of IC50 in the cytoplasm. Rho-DDTC can also be used to reveal the 
intracellular reduction of several platinum(IV) prodrugs and the accumulation of 
their platinum(II) products in the cytoplasm. The distribution of PtIV(OH)2 is 
similar to that of cisplatin, whereas PtBz accumulates outside the nucleus. Co-
staining with organelle antibodies suggests that PtBz accumulates in the 
endoplasmic reticulum (ER) without causing ER stress. Combined with the results 
from Chapters 2 and 3, the data suggest that PtBz acts similarly to cisplatin in terms 
of its mode of action, where the reduced platinum(II) PtBz species migrates toward 
the nucleus to bind with DNA and induce cell death.  
 
4.4 Experimental Procedures 
4.4.1 Materials 
Chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA) unless 
otherwise stated. Satraplatin and JM118 were purchased from Merlin Chemicals 
Ltd (Liphook, UK). K2PtCl4 was purchased from Furaya Metals (Tokyo, Japan). 
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Cisplatin, PtIV(OH)2 and PtBz were prepared as described elsewhere.
17,18,19,20 
Plasmid pET 23/42 was given as a kind gift from Dr Chng Shu Sin (Department of 
Chemistry, NUS). Primary rabbit monoclonal antibodies AIF (D39D2), EEA1 
(C45B10), LAMP1 (D2D11), PDI (C81H6), RCAS1 (D2B6N), NUP98 (C39A3) 
and secondary Alexa Fluor 488-conjugated anti-rabbit IgG (H+L) (#4412) were 
purchased from Cell Signaling Technology (Beverly, MA, USA). Protease inhibitor 
was prepared from Pierce Protease Inhibitor Minitablets (#88665) (Pierce 
Biotechnology, Rockford, IL, USA).  
 
4.4.2 Instruments 
Emission fluorescence spectra were recorded on a JOBIN YVON Fluorolog by 
HORIBA (Kyoto, Japan) (λex 490 nm) with an iHR320 detector. Images were 
captured with Olympus FluoView FV1000 (Olympus, Japan) laser scanning 
confocal microscope using a 60×/1.00 water objective, with a 543-nm HeNe laser 
as the excitation source.  
 
4.4.3 Cell culture 
All cultures were maintained in a humidified incubator with 5% CO2 at 37°C unless 
otherwise stated. A2780 and HeLa cells were cultured in Roswell Park Memorial 
Institute (RPMI)-1640 medium supplemented with 10% FBS and 1% antibiotics. 
Ishikawa cells were cultured in Minimum Essential Medium Eagle (MEME) 




4.4.5 Cellular imaging of Rho-DDTC with different cisplatin concentration  
HeLa cells were seeded on coverslips placed into the wells of 6-well plates at a 
density of 20 × 104 cells per mL and incubated overnight before treatment. During 
treatment, the cells were incubated for 3 h with media containing either blank or 
cisplatin at different concentration (as multiple of IC50; set at 3 µM). After 3 h 
incubation, the cells were washed twice with 1× PBS. Subsequently, the cells were 
incubated in medium containing Rho-DDTC (30 μM) for 1 h. The cells were 
washed twice with 1× PBS, fixed with 4% paraformaldehyde for 15 min, stained 
with Hoechst 33342 nuclear stain (1.2 μg/mL) and then washed twice with 1× PBS. 
 
4.4.6 Platination of plasmid pET 23/42 
The plasmid (50 nM) was reacted with cisplatin (50, 100, 200, 300 μM) in buffer 
(240 mM HEPES pH 6.0, 10 mM NaCl) for 24 h at 25°C. The reaction mixture was 
dialyzed against TE/NaCl buffer (10 mM Tris.HCl pH 8.0, 1 mM EDTA, 200 mM 
NaCl) for 4 h and TE buffer (10 mM Tris.HCl pH 8.0, 1 mM EDTA) for 8 h with 
two exchanges of TE buffer solution. The sample was then precipitated with ethanol 
and reconstituted in water. 
 
4.4.7 Reaction of Rho-DDTC with platinated plasmid  
Platinated plasmids (5 nM) were reacted with Rho-DDTC (50 μM) in buffer (10 
mM HEPES, 30% ethanol, 5% DMSO) for 24 h at 50°C. Fluorescence values 
(excitation/emission, 490/585 nm) for each sample was recorded using a 
fluorescent spectrophotometer.  
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4.4.8 Cellular imaging of Rho-DDTC with different platinum complexes 
HeLa cells were seeded on coverslips placed into the wells of 6-well plates at a 
density of 20 × 104 cells per mL and incubated overnight before treatment. During 
treatment, the cells were incubated for 3 h with media containing either (a) blank 
media, (b) cisplatin, (c) JM118, (d) oxaliplatin, (e) PtIV(OH)2, (f) PtBz, (g) 
satraplatin (30 μM). After 3 h incubation, the cells were washed twice with 1× PBS. 
Subsequently, the cells were incubated in medium containing Rho-DDTC (30 μM) 
for 1 h. The cells were washed twice with 1× PBS, fixed with 4% paraformaldehyde 
for 15 min, stained with Hoechst 33342 nuclear stain (1.2 μg/mL) and then washed 
twice with 1× PBS.  
 
4.4.9 Cellular localization of platinum complexes 
Ishikawa cells were seeded on coverslips placed into the wells of 6-well plates at a 
density of 10 × 104 cells per mL and incubated overnight before treatment. During 
treatment, the cells were treated with media containing PtBz (20 µM) for 3 h. The 
cells were then washed twice with 1× PBS. Subsequently, the cells were fixed with 
4% paraformaldehyde for 15 min and then wash three times with 1× PBS. Cells 
were then blocked in blocking buffer (5% BSA, 0.3% Triton™ X-100 in 1× PBS) 
for 1 h and then incubated overnight at 4°C with primary antibody diluted in 
antibody dilution buffer (1% BSA, 0.3% Triton™ X-100 in 1× PBS). Cells were 
then rinsed three times with 1× PBS and then incubated for 1 h with secondary 
antibody diluted in antibody dilution buffer. The cells were washed three times with 
1× PBS, and incubated with media containing Rho-DDTC (20 μM) at 37°C for 1 h. 
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The cells were washed twice with 1× PBS, stained with Hoechst 33342 nuclear 
stain (1.2 μg/mL), and then washed three times with 1× PBS. Pearson’s 
colocalization coefficient (PCC) calculated using ImageJ plug-in JACoP (Just 
Another Co-localization Plug-in). 
 
4.4.10 Immunoblotting for CHOP protein 
Immunoblotting for CHOP protein was performed on cell lysates from A2780 cells. 
Approximately 5 × 105 A2780 cells were seeded into the wells of a 6-well plates 
and incubated overnight. Cells were then treated with cisplatin (1× IC50 3.32 μM), 
oxaliplatin (1× IC50 1.09 μM), or PtBz (1× IC50 0.07 μM) for 24 h. Cells were 
washed three times with 1× PBS and then lysed in 100 µL of ice-cold lysis buffer 
(50 mM Tris pH 8.0, 150 mM NaCl, 1× protease inhibitor, 1% IGEPAL). Cells 
were collected using a cell scraper and centrifuged at 16,000 x g for 20 min at 4°C. 
A Bradford assay was used to quantify the protein concentration in each sample. 
Protein (50 µg) was loaded and resolved on a 10% SDS-polyacrylamide gel. 
Proteins were then transferred onto a nitrocellulose membrane and blocked with 5% 
non-fat milk (1× D-PBS, 0.1% Tween-20) for 1 h at room temperature. The 
membrane was then stained with primary antibodies diluted in 1% non-fat milk (1× 
D-PBS, 0.1% Tween-20) overnight at 4°C, washed three times with wash buffer 
(1× D-PBS, 0.1% Tween-20), and then incubated with secondary antibody (diluted 
in 1% non-fat milk in 1× D-PBS, 0.1% Tween-20) for 2 h at room temperature. The 
membrane was washed three times with wash buffer and then visualized using 
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Luminata Crescendo Western HRP substrate (Merck Millipore Corporation, 
Darmstadt, Germany) and imaged with G:Box (Syngene, Cambridge, UK). 
 
4.5 References 
1. Alderden, R. A.; Hall, M. D.; Hambley, T. W., The Discovery and Development 
of Cisplatin. J. Chem. Educ. 2006, 83 (5), 728. 
2. Harper, B.; Krause-Heuer, A.; Grant, M.; Manohar, M.; Garbutcheon-Singh, K. 
B.; Aldrich-Wright, J., Advances in Platinum Chemotherapeutics. Chem. Eur. 
J. 2010, 16 (24), 7064-7077. 
3. van Rijt, S. H.; Sadler, P. J., Current applications and future potential for 
bioinorganic chemistry in the development of anticancer drugs. Drug Discovery 
Today 2009, 14 (23-24), 1089-1097. 
4. Barnes, K. R.; Kutikov, A.; Lippard, S. J., Synthesis, Characterization, and 
Cytotoxicity of a Series of Estrogen-Tethered Platinum(IV) Complexes. Chem. 
Biol. 2004, 11 (4), 557-564. 
5. Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J., Targeted 
delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) 
prodrug-PLGA-PEG nanoparticles. Proc. Nat. Acad. Sci. U.S.A. 2008, 105 (45), 
17356-61. 
6. Carr, J. L.; Tingle, M. D.; McKeage, M. J., Satraplatin activation by 
haemoglobin, cytochrome C and liver microsomes in vitro. Cancer Chemother. 
Pharmacol. 2006, 57 (4), 483-490. 
7. Olszewski, U.; Ach, F.; Ulsperger, E.; Baumgartner, G.; Zeillinger, R.; 
Bednarski, P.; Hamilton, G., In Vitro Evaluation of Oxoplatin: An Oral 
Platinum(IV) Anticancer Agent. Met. Based Drugs 2009, 2009, 348916. 
8. Molenaar, C.; Teuben, J. M.; Heetebrij, R. J.; Tanke, H. J.; Reedijk, J., New 
insights in the cellular processing of platinum antitumor compounds, using 
fluorophore-labeled platinum complexes and digital fluorescence microscopy. 
J. Biol. Inorg. Chem. 2000, 5 (5), 655-665. 
9. Safaei, R.; Katano, K.; Larson, B. J.; Samimi, G.; Holzer, A. K.; Naerdemann, 
W.; Tomioka, M.; Goodman, M.; Howell, S. B., Intracellular Localization and 
Trafficking of Fluorescein-Labeled Cisplatin in Human Ovarian Carcinoma 
Cells. Clin. Cancer Res. 2005, 11 (2), 756-767. 
10. New, E. J.; Duan, R.; Zhang, J. Z.; Hambley, T. W., Investigations using 
fluorescent ligands to monitor platinum(iv) reduction and platinum(ii) reactions 
in cancer cells. Dalton Trans. 2009,  (16), 3092-3101. 
106 
 
11. Montagner, D.; Yap, S. Q.; Ang, W. H., A Fluorescent Probe for Investigating 
the Activation of Anticancer Platinum(IV) Prodrugs Based on the Cisplatin 
Scaffold. Angew. Chem. Int. Ed. 2013, 125 (45), 12001-12005. 
12. Giovagnini, L.; Ronconi, L.; Aldinucci, D.; Lorenzon, D.; Sitran, S.; Fregona, 
D., Synthesis, Characterization, and Comparative in Vitro Cytotoxicity Studies 
of Platinum(II), Palladium(II), and Gold(III) Methylsarcosinedithiocarbamate 
Complexes. J. Med. Chem. 2005, 48 (5), 1588-1595. 
13. Montagner, D.; Sanz Miguel, P. J., Unique Pt5 metallacycle: 
[PtIICl(pyrrolidinedithiocarbamate)]5. Dalton Trans. 2011, 40 (41), 10809-
10811. 
14. Borch, R. F.; Pleasants, M. E., Inhibition of cis-platinum nephrotoxicity by 
diethyldithiocarbamate rescue in a rat model. Proc. Nat. Acad. Sci. U.S.A. 1979, 
76 (12), 6611-6614. 
15. Bodenner, D. L.; Dedon, P. C.; Keng, P. C.; Katz, J. C.; Borch, R. F., Selective 
Protection against cis-Diamminedichloroplatinum(II)-induced Toxicity in 
Kidney, Gut, and Bone Marrow by Diethyldithiocarbamate. Cancer Res. 1986, 
46 (6), 2751-2755. 
16. Awni, W. M.; Hoff, J. V.; Shapiro, B. E.; Halstenson, C. E., A Dose-Ranging 
Pharmacokinetics Study of Sodium Diethyldithiocarbamate in Normal Healthy 
Volunteers. J. Clin. Pharmacol. 1994, 34 (12), 1183-1190. 
17. Dhara, S. C., A Rapid Method for the Synthesis of cis-[Pt(NH3)2Cl2]. Indian 
J. Chem. 1969, 8, 193-194. 
18. Ang, W. H.; Khalaila, I.; Allardyce, C. S.; Juillerat-Jeanneret, L.; Dyson, P. J., 
Rational design of platinum(IV) compounds to overcome glutathione-S-
transferase mediated drug resistance. J. Am. Chem. Soc. 2005, 127, 1382-1383. 
19. Ang, W. H.; Pilet, S.; Scopelliti, R.; Bussy, F.; Juillerat-Jeanneret, L.; Dyson, 
P. J., Synthesis and Characterization of Platinum(IV) Anticancer Drugs with 
Functionalized Aromatic Carboxylate Ligands:  Influence of the Ligands on 
Drug Efficacies and Uptake. J. Med. Chem. 2005, 48 (25), 8060-8069. 
20. Chin, C. F.; Tian, Q.; Setyawati, M. I.; Fang, W.; Tan, E. S.; Leong, D. T.; Ang, 
W. H., Tuning the Activity of Platinum(IV) Anticancer Complexes through 
Asymmetric Acylation. J. Med. Chem. 2012, 55 (17), 7571-7582. 
21. Chen, X.; Jia, J.; Ma, H.; Wang, S.; Wang, X., Characterization of rhodamine 
B hydroxylamide as a highly selective and sensitive fluorescence probe for 





4.6 Supplementary information 
4.6.1 Synthesis of compound 1 
Compound 1 was synthesized and purified by Dr Diego Montagner as reported in 
the literature.21 
 
4.6.2 Synthesis of compound 2 
Compound 2 was synthesized and purified by Dr Diego Montagner. Compound 1 
(346 mg, 0.75 mmol) was dissolved in DMF (1 mL). TEA (379 mg, 3.75 mmol) 
and 1,2-dibromoethane (351 mg, 1.87 mmol) were added to the solution. The 
mixture was then stirred at room temperature in the dark for 18 h. The reaction 
mixture was taken up to 60 mL with DCM, washed with NaHCO3 (1 M, 2 × 50 mL) 
and the organic layer set aside. The aqueous phase was re-extracted with DCM (100 
mL) before the organic layers were combined and washed with NaCl (3 M, 50 mL). 
The organic extract was dried over Na2SO4 and purified through flash column 
chromatography using EA:hexane 1:4 as eluent. The desired product was obtained 
as a light pink powder (248 mg, 0.44 mmol, 61% yield, Rf= 0.31). 
1H NMR CDCl3: 
δ 7.92 (d,3JHH 6.9, 1H, H12); 7.49 (m, 2H, H10 and H11); 7.09 (d,1JHH 6.9, 1H, H9); 
6.49 (d, 3JHH 8.8,2H, H4 and H4’); 6.40 (s, 2H, H2 and H2’); 6.30 (d,1JHH 8.8, 2H, 
H5 and H5’); 3.94 (t, 3JHH 7.1, 2H, H16); 3.34 (q, 3JHH 7.1, 8H, H20); 3.23 (t, 3JHH 






4.6.3 Synthesis of Rho-DDTC 
Rho-DDTC was synthesized and purified by Dr Diego Montagner. Compound 2 
(118 mg, 0.21 mmol) was dissolved in DMF (3 mL). NaDDTC (52.3 mg, 0.23 
mmol) was added and the reaction mixture was stirred for 20 min in the dark until 
completion (checked by thin layer chromatography). The solution was dried in a 
vacuum and the residue reconstituted in 10 mL DCM. The mixture was filtered to 
remove the white solid (NaBr and unreacted NaDDTC) and the solvent was 
removed to obtain a light purple solid (120 mg, 0.19 mmol, 91% yield). Crystals 
suitable for single crystal X-ray diffraction analyses were obtained via slow 
evaporation from acetonitrile solution. 1H NMR CDCl3: δ 7.92 (d,3JHH 6.9, 1H, 
H12); 7.47 (m, 2H, H10 and H11); 7.08 (d,1JHH 6.9, 1H, H9); 6.54 (d, 
3JHH 8.6,2H, 
H4 and H4’); 6.39 (s, 2H, H2 and H2’); 6.29 (d,1JHH 8.6, 2H, H5 and H5’); 3.94 (m, 
4H, H16 and H18); 3.73 (q, 3JHH 5.3, 2H, H18’); 3.45 (q, 3JHH 5.3, 2H, H15); 3.33 
(q, 3JHH 7.1, 8H, H20); 1.28 (t, 
3JHH 5.3, 3H, H19); 1.21 (t, 
3JHH 5.3, 3H, H19’); 
1.17 (t, 3JHH 7.1, 12H, H21). 1H NMR DMSO: δ 7.82 (d,3JHH 6.7, 1H, H12); 7.56 
(m, 2H, H10 and H11); 7.04 (d,1JHH 6.7, 1H, H9); 6.37 (m, 6H, H4, H4’, H5, H5’, 
H6 and H6’); 3.87 (q, 3JHH 6.9; 2H, H18); 3.78 (t, JHH 6.1; 2H, H16); 3.66 (q, 3JHH 
6.9, 2H, H18’); 3.46 (overlapped with DMSO, 8H, H20); 3.18 (t, 3JHH 6.1, 2H, H15); 
3.33 (q, 3JHH 7.1, 8H, H20); 3.23 (t, 
3JHH 7.1, 2H, H15); 1.25 5 (t, 
3JHH 5.5, 3H, 
H19); 1.19 (t, 3JHH 5., 3H, H19’); 1.06 (t, 3JHH 6.7, 12H, H21). 13C NMR CDCl3: δ 
195.6 (C17); 165.2 (C14); 153.5 (C1 and C1’); 150.5 (C13); 148.9 (C3 and C3’); 
133.1 (C8); 129.3 (C12); 129.0 (C6 and C6’); 128.3 (C4 and C4’); 123.9 
(C10);123.0 (C11); 108.5 (C2 and C2’); 105.1 (C9); 98.1 (C5 and C5’); 75.4 (C15); 
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65.4 (C7); 49.5 (C18); 46.7 (C18’); 44.2 (C20); 35.8 (C16); 12.5 (C21); 11.6 (C19 
and C19’). 13C NMR DMSO: δ 193.8 (C17); 164.3 (C14); 153.6 (C1 and C1’); 
150.4 (C13); 148.9 (C3 and C3’); 134.0 (C8); 129.3 (C12); 129.2 (C6 and C6’); 
128.8 (C4 and C4’); 124.2 (C10);123.0 (C11); 108.5 (2 and C2’); 104.8 (C9); 97.8 
(C5 and C5’); 74.8 (C15); 65.1 (C7); 49.6 (C18); 46.9 (C18’); 44.1 (C20); 35.0 









Figure S4.2. 13C NMR of Rho-DDTC in CDCl3. 
 
 





Figure S4.4. Fluorescence intensity of Rho-DDTC (10 µM) in different pH 
conditions (λex 490 nm, λem 584 nm). Determined by Dr Diego Montagner. 
 
 
Figure S4.5. Absorbance profile of Rho-DDTC (20 µM) in buffer (20 mM HEPES, 
pH 7.4, 30% v/v EtOH) upon the addition of Pt2+; (Inset) Plot of absorbance 
intensity at 565 nm against [Pt2+]. Determined by Dr Diego Montagner. 
 
 
Figure S4.6. Fluorescence profile of Rho-DDTC (20 µM) in buffer (20 mM 
HEPES, pH 7.4, 30% v/v EtOH) upon the addition of Pt2+; (Inset) Plot of 





Figure S4.7. Job’s plot of a 1:1 complex between Rho-DDTC (10 µM) and Pt2+ in 
water. Difference in fluorescence intensity (λex 490 nm, λem 584 nm) was plotted 
against the mole fraction of [Pt2+]. Determined by Dr Diego Montagner. 
 
 
Figure S4.8. Fluorescence profile of Rho-DDTC (20 µM) in buffer (20 mM 
HEPES, pH 7.4, 30% v/v EtOH) upon the addition of cisplatin; (Inset) Plot of 
fluorescence intensity (λex 490 nm, λem 584 nm) against [cisplatin]. Determined by 
Dr Diego Montagner. 
 
 
Figure S4.9. (Left) Fluorescence intensity (λex 490 nm, λem 584 nm) of Rho-DDTC 
(20 µM) to 1 equivalent of metals ions in buffer (20 mM HEPES, pH 7.4, 30% v/v 
EtOH). (Right) Fluorescence profile (λex 490 nm) of Rho-DDTC to metals ions in 






Figure S4.10. (Top) Fluorescence profile (λex 490 nm) of Rho-DDTC (20 µM) in 
buffer (20 mM HEPES, pH 7.4, 30% v/v EtOH) to cisplatin and other metals ions 
in physiological concentration; (Bottom) Fluorescence intensity (λex 490 nm, λem 
584 nm) of Rho-DDTC (20 µM) in buffer (20 mM HEPES, pH 7.4, 30% v/v EtOH) 




Figure S4.11. Fluorescence profile (λex 490 nm) of Rho-DDTC (20 µM) in buffer 
(20 mM HEPES, pH 7.4, 30% v/v EtOH) to different platinum(II) complexes (10 




Figure S4.12. Fluorescence profile (λex 490 nm) of Rho-DDTC (20 µM) in buffer 
(20 mM HEPES, pH 7.4, 30% v/v EtOH) to different platinum complexes (20 µM). 





Figure S4.13. Fluorescence imaging of HeLa cells treated with cisplatin at different 
concentrations (as multiple of IC50; set at 3 µM) for 3 h and further incubated with 
Rho-DDTC (30 µM) for 1 h at 37°C. Cells were fixed with 4% paraformaldehyde 





Figure S4.14. Fluorescence image of HeLa cells treated with 30 µM of different 
platinum complexes for 3 h and further incubated with Rho-DDTC (30 µM) for 1 
h at 37°C. Cells were fixed with 4% paraformaldehyde and stained with and 




Figure S4.15. Fluorescence image of Ishikawa cells treated with 30 µM of PtBz 
(30 µM) for 3 h at 37°C, fixed with 4% paraformaldehyde, stained with antibody 
and further incubated with Rho-DDTC (30 µM) for 1 h at 37°C. Cells were 




Figure S4.16. CHOP expression of cells treated with cisplatin (1× IC50 3.32 μM), 
oxaliplatin (1× IC50 1.09 μM), PtBz (1× IC50 0.07 μM) for 24 h. Tharpsigargin (Tg) 
was used as a positive control for CHOP expression. 
 
Table S4.1. Probe activation of Rho-DDTC with different platinum(II) 
pharmacophores. Determined by Dr Diego Montagner. 













chelating leaving group: 





chelating amine ligands: 








Am = NH3 and C6H11NH2  







chelating amine ligand 
and leaving group: 









Table S4.2. Pearson’s colocalization coefficient (PCC) calculated for fluorescence 
image of Rho-DDTC and antibody of respective organelles. 
 Pearson’s colocalization coefficient (PCC)a 
Mitochondria 0.17 ± 0.03 
Endosome 0.52 ± 0.05 
Lysosome 0.40 ± 0.01 
Nuclear membrane 0.32 ± 0.01 
Endoplasmic reticulum 0.96 ± 0.00 
Golgi 0.44 ± 0.08 
aPearson’s colocalization coefficient (PCC) calculated using ImageJ plug-in JACoP (Just Another 
Co-localization Plug-in). PCC varies from -1 to 1, -1 stating for full exclusion, 0 stating the absence 
of correlation and 1 stating for full correlation. Data represent averages and standard error means of 




In vivo pharmacological evaluation of platinum(IV) 




Platinum-based anticancer drugs namely, cisplatin, carboplatin and oxaliplatin, 
have been the mainstay in cancer chemotherapy for several decades. However, the 
premature aquation and inactivation of these platinum(II) drugs has meant that they 
have limited clinical utility.1,2 Consequently, there is a growing interest in the use 
of inert platinum(IV) complexes as prodrugs to circumvent these limitations. These 
prodrugs comprise an additional two axial ligands that allow fine-tuning of their 
physicochemical and biological properties.2,3,4 
 
Satraplatin, one of the three platinum(IV) complexes evaluated clinically, was 
specifically designed to overcome the limitation faced by platinum(II)-based 
anticancer drugs.5,6 Its high solubility and stability in acidic environments 
warranted its oral administration as compared with the traditional route of 
platinum(II) drug administration by intravenous injection.7 Satraplatin has been 
evaluated in various cancer chemotherapy trials, including Phase I through to Phase 
III trials.8,9,10,11,12 However, the Food and Drug Administration of the United States 
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of America rejected the application for the use of satraplatin in a clinical context, 
as the prodrug did not increase overall survival significantly.13,14  
 
The symmetrical, hydrophilic axial ligands of satraplatin improve only on its 
solubility, without affecting its efficacy. Yet, the addition of symmetrical lipophilic 
ligands would likely improve the activity of the prodrug (Figure 5.1). However, 
these lipophilic additions would unavoidably cause the prodrug to be insoluble in 
aqueous medium, and thus the compound would not fall within the optimal 
biological efficacy range. To this end, our group has solved a way to attach 
asymmetrical ligands onto platinum(IV) complexes to fine-tune its properties for 
optimal efficacy.15 These asymmetric-platinum(IV) complexes bear axial acetyl 
ligands, which improve the compound’s solubility while leaving the other axial 
ligands available to improve the stability and cytotoxicity of the compound.15,16 
Thus, we hypothesized that these asymmetric-platinum(IV) complexes with a 
balance in their cytotoxicity, physical and chemical properties (fine-tuned by 
asymmetrical axial ligands) would display superior in vivo activity as compared to 
other complexes.  
 
To examine this hypothesis, three complexes (A3, A9 and A14; Figure 5.1) have 
been selected from the 21 asymmetric-platinum(IV) complexes designed and 
synthesized by Dr Chin Chee Fei. These complexes were chosen for their solubility, 
permeability, rate of reduction and in vitro cytotoxicity in ovarian cancer cell line.16 
The  following Chapter sought to examine the hypothesis by testing the efficacy of 
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the compounds as orally applicable drug in a in vivo model of colorectal cancer 
(CRC).  
 
Figure 5.1. Chemical structures of platinum(II) and platinum(IV) complexes evaluated for their 
suitability for clinical use. 
 














Cisplatin 3.37 ± 0.05 - - 2.56 ± 1.97 -2.03 ± 0.47 
A3 0.26 ± 0.06 >3 days 20.0 ± 1.4 1.01 ± 0.45 0.28 ± 0.05 
A9 0.30 ± 0.01 >3 days 3.3 ± 0.1 0.85 ± 0.56 0.56 ± 0.01 
A14 1.97 ± 0.02 >3 days 0.9 ± 0.0 4.14 ± 0.23 -0.41 ± 0.02 
aComplexes were dissolved in 8 mL of water to saturation and filtered. [Pt] was determined using 
ICP-OES. bStability of platinum(IV) complexes in 40 mM HEPES buffer; [Pt] measured by HPLC-
UV. cRate of reduction of platinum(IV) complexes treated with 3 mM ascorbic acid, reduction of 
platinum(IV) complexes was assumed to follow first-order kinetics and the depletion of platinum 
complexes was monitored via HPLC-UV. dIC50 values is the concentration of Pt complexes required 
to inhibit 50% of cell growth with respect to control groups, as measured by MTT assay after 6 h 
drug exposure and 66 h of incubation in A2780 human ovarian cancer cells. eLog Pow values were 
determined with the shake flask method using n-octanol and ultrapure water. Data represent 
averages and standard deviations of three independent experiments. IC50 values were corrected 
using actual [Pt] concentrations measured by ICP-OES. Data adapted from ref16. 
 
5.2 Results and Discussion 
5.2.1 Cytotoxicity of platinum complexes 
To show that the selected platinum(IV) compounds (A3, A9 and A14) are active 
against colorectal cancer cells, a cell viability assay was performed. This section of 
the work was carried out in collaboration with Dr. Ho Han Kiat and Dr Pang Yi 
Yun. MTT assay was used to determine the IC50 values of the drugs in two 
123 
 
colorectal cancer (CRC) cell lines (HCT116 and HT29) and the LC50 values in a 
non-cancerous cell line (immortalized murine transforming growth factor-alpha 
(TGF-α) transgenic hepatocyte, TAMH). Generally, HT29 cells, which carry a 
mutant form of p53, were more resistant to the platinum drugs than HCT116 cells, 
which carry the wild-type p53 gene.17,18,19 Of the drugs tested, oxaliplatin is 1.8- 
and 1.6-fold more active than cisplatin in the HCT116 and HT29 CRC cell lines, 
respectively (Table 5.2). The reason for this superior activity of oxaliplatin is not 
clear but may be attributable to the formation of oxaliplatin-DNA adducts, which 
are more difficult to repair by a mismatch repair protein.20,21,22,23 Satraplatin 
performed better than cisplatin in HCT116 cells (1.7-fold increase in cytotoxicity) 
and HT29 cells (4.6-fold increase over cisplatin). Satraplatin is thus equally active 
in both colorectal cell lines; this characteristic is not shared by cisplatin and 
oxaliplatin. These results correlate well with the literature, where the activity of 
satraplatin is independent of p53 status in CRC cell lines.24 
 
Table 5.2. Cytotoxicity data for platinum complexes. 









Compound HCT116 HT29 
Cisplatin 3.69 ± 0.20 10.99 ± 0.90 20.59 ± 1.65 5.6 1.9 
Oxaliplatin 2.02 ± 0.13 6.64 ± 0.46 >50 25 8 
Satraplatin 2.14 ± 0.25 2.41 ± 0.33 14.13 ± 0.56 6.6 5.8 
A3 0.36 ± 0.00 1.25 ± 0.16 3.04 ± 0.14 8.4 2.4 
A9 2.33 ± 0.03 4.99 ± 0.71 7.72 ± 0.44 3.3 1.5 
A14 4.16 ± 0.53 6.95 ± 0.20 >20 >5 >3 
aIC50 values represent the concentration of Pt complexes required to inhibit 50% of cell growth with 
respect to control groups, as measured by MTT assay after 72 h drug exposure.  bLC50 values 
represent the concentration of Pt complexes required to inhibit 50% of cell growth with respect to 
control groups, as measured by MTT assay after 24 h drug exposure. Data represent averages and 
standard deviations of three independent experiments. IC50 values were corrected using actual [Pt] 




All three asymmetric-platinum(IV) complexes (A3, A9 and A14) remained active 
in both CRC cell lines, with their IC50 fall within the range of 0.36–4.16 µM and 
1.25–6.95 µM for HCT116 and HT29 cells, respectively. Complex A3 was 
remarkably active (10.2- and 8.8-fold more cytotoxic, respectively) and possessed 
a higher safety ratio than cisplatin, whereas complex A9 had the lowest safety ratio 
despite having good activity against the two cell lines. Although complex A14 
performed worst among the asymmetric-platinum(IV) complexes, it had a better 
safety ratio than the more cytotoxic asymmetric-platinum(IV) complexes. From 
these tests, complexes A3, A9 and A14 were chosen to evaluate their toxicities and 
antitumoral activity in mice, using cisplatin and satraplatin as positive controls.  
 
5.2.2 Evaluation of in vivo dose and frequency  
To determine the dosage and frequency of the drugs, platinum complexes were 
administered via oral gavage (p.o.) or intraperitoneal (i.p.) injection into mice. This 
section of the work was carried out in collaboration with Dr. Ho Han Kiat and Dr 
Pang Yi Yun. The low organic/aqueous partition of cisplatin ruled out the 
possibility of an oral formulation; thus cisplatin was administered via an i.p. 
injection.25 Among the platinum complexes evaluated, cisplatin was least tolerated 
in mice at a dose of 5 mg/kg i.p. once a week (Table 5.3). Comparatively, the three 
asymmetric-platinum(IV) complexes were well tolerated in mice, even at a higher 
dose than that used for cisplatin via i.p.injection. Dosages higher than 15 mg/kg i.p. 
were not pursued, as mice treated with complex A3 at 15 mg/kg (thrice a week) 
started to show signs of toxicity after 2 weeks on the drug. Among all the complexes, 
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satraplatin was best tolerated in mice, with up to 60 mg/kg i.p. per week able to be 
administered as compared with 15 mg/kg per week for the asymmetric-platinum(IV) 
complexes. Dosages over 20 mg/kg p.o. were not pursued in view of the time and 
amount of compound consumed. 
 








Total dose/ week 
(mg/kg) 
Cisplatin i.p. 5 1 5 
Satraplatin i.p. 15 3 45 
p.o. 20 3 60 
A3 i.p. 15 1 15 
p.o. 20 3 60 
A9 i.p. 15 1 15 
p.o. 20 3 60 
A14 i.p. 15 1 15 
p.o. 20 3 60 
 
5.2.3 Tissue distribution of platinum complexes in mice 
To evaluate the tissue distribution of platinum complexes in mice, all mice were 
treated i.p. or p.o. for 2 weeks with the optimized doses (Figures 5.2 and 5.3). This 
section of the work was carried out in collaboration with Dr. Ho Han Kiat and Dr 
Pang Yi Yun. At the end of the 2-week cycle, organs were collected and platinum 
concentrations in the various tissues were determined by ICP-MS. Overall, all 
platinum complexes shared the same distribution profile regardless of the 
administration route. Equilibrium in terms of platinum distribution also occurred 
between the blood stream and various organ tissues, such as the liver and kidney. 
Low platinum concentrations were found in the brain tissue, suggesting that 
platinum complexes are unlikely to cross the blood-brain barrier. The low platinum 
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concentration in the brain tissue also suggests that the drug molecules (and their 
metabolites) are more hydrophilic and eliminated via the kidney (higher platinum 
concentration in kidney than brain).  
 
The platinum concentrations in various tissues were higher when the drugs were 
introduced via the i.p. route. The peritoneal cavity forms a sink for the drug, and 
allows the drug to slowly permeate into the nearby blood capillaries. In comparison, 
drugs administered via the p.o. route may be excreted in the feces, which leaves 
less drug available for adsorption along the gastrointestinal tract. The results of the 
present study found high platinum concentrations in the blood, liver and kidney for 
all platinum complexes introduced via the p.o. route. This suggests that platinum 
complexes can permeate through the gastrointestinal cellular membrane, enter the 
blood stream and be distributed systematically. The portal vein tributaries from the 
intestine carry the drug directly to the liver, which results in a higher platinum 
concentration in the liver than in the kidney.  
 
 
Figure 5.2. Average platinum accumulation after p.o. administration of platinum(IV) complexes in 
different tissues and blood from two healthy female C57BL6 mice per compound. Data represent 




Figure 5.3. Average platinum accumulation after i.p. administration of platinum(IV) complexes in 
different tissues and blood from two healthy female C57BL6 mice per compound. Data represent 
averages and standard error means. 
 
5.2.4 Design and optimization of a colitis-induced CRC mouse model  
A colitis-induced CRC model was chosen to assess the antitumoral activities of the 
asymmetric-platinum(IV) complexes. This section of the work was carried out in 
collaboration with Dr. Ho Han Kiat and Dr Pang Yi Yun. Given that there are 
several ways to induce CRC,26,27 a systematic approach was undertaken, first using 
just one cycle of AOM/DSS treatment (Figure 5.4). This single-treatment approach 
led to only 0–2 tumors on three mice sacrificed on Day 28. Hence, the experiment 
was prolonged until Day 56, where another three mice were sacrificed. These mice 
displayed thickened walls at the distal end of the colon as well as small polyps but 
incidence of tumor formation was low (Figure S5.1). At Day 84, six mice showed 
large variations in tumor formation (Figure S5.1). From these results, it was deemed 
that one cycle of AOM/DSS treatment was insufficient to induce tumor formation, 








Weight loss in the mice was observed during the second AOM/DSS treatment cycle 
(Figure 5.5). However, no rectal bleeding was observed. Three mice were sacrificed 
on Day 56. These mice showed thickened distal colon walls and the formation of 
numerous small polyps but, again, tumor formation rates were low (Figure S5.2). 
Because of these low tumor formation rates from two cycles of AOM/DSS 
treatment, the remaining mice were not sacrificed as planned but treated with a third 
cycle of AOM/DSS. 
 
 
Figure 5.5. Timeline for two cycles of AOM/DSS treatment. Treatment in the box were planned 
but not carried out. 
 
During the third AOM/DSS treatment cycle (Figure 5.6), weight loss and rectal 
bleeding were observed. Nine mice were sacrificed on Day 84. The formation of 
129 
 
tumors was more noticeable, with several of the mice showing numerous large and 
visible tumors within their colons (Figure S5.3). Nevertheless, tumor formation 
rates still varied, with some mice having low tumor formation. It was therefore 
deemed that multiple injections of AOM were not necessary in the CRC model. 
 
 
Figure 5.6. Timeline for three cycles of AOM/DSS treatment. 
 
In previous work, tumors were induced in the mice by exposure to azoxymethane 
(AOM) followed by repeated exposure to dextran sodium sulfate (DSS) and water 
cycles.26,27 Exposure to the AOM carcinogen induces colorectal tumor formation in 
mice, whereas the DSS induced inflammation. Administration of water after DSS 
exposure allows the colonic mucosa to heal. The repetition of such DSS/water cycle 
augments the effect caused by AOM.28  
 
Thus, the number of AOM injections was decreased back to one and instead, the 
concentration of DSS was increased to 2% and coupled with three cycles of 




5.2.5 In vivo efficacy of platinum complexes in colitis-induced colorectal cancer 
mouse model 
Evaluating the in vivo efficacy of platinum complexes consisted of five arms of the 
experiment for p.o. administration: vehicle control, three test compounds (A3, A9 
and A14) and the positive control satraplatin. Each arm comprised 6 mice. All mice 
were treated with 10 mg/kg AOM followed by three cycles of DSS/water (Figure 
5.7).  From Day 70, mice received 20 mg/kg of platinum compounds, thrice a week 
for two weeks, while the vehicle control mice received 0.6% methyl cellulose (MC) 
in saline without platinum compounds. Mice were sacrificed on Day 84, and the 
efficacy of the platinum compounds was examined. This section of the work was 
carried out in collaboration with Dr. Ho Han Kiat and Dr Pang Yi Yun. 
Representative images of the tumors in the colons can be found in Figure S5.4. 
 
 
Figure 5.7. Timeline for in vivo evaluation of platinum complexes in colitis-induced colorectal 
cancer model. 
 
The mean tumor burden in each group varied in each treatment group due to the 
high variability in tumor number (Figure 5.8). This is likely because the induction 
of tumor formation in the colitis-induced CRC model is more natural than, for 
example, a xenograph model, where the tumor is implanted onto the mice. Thus, 
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tumor formation in the CRC model is far less controllable than in a xenograph 
model, which helps to explain the high variability in the number of tumors formed. 
Overall, mice responded well to treatment with the A14 compound, with a 
reduction in tumor diameter as compared with the vehicle group. In contrast, 
satraplatin, A3 and A9 treatment only caused a modest reduction in tumor diameter, 
with high fluctuations in the tumor diameters observed.  
 
The efficacy of the platinum compounds in the treatment of colitis-induced CRC 
correlates well with the solubility and reduction rates (in 3 mM ascorbic acid). 
Among all platinum complexes evaluated, compound A14 had the highest 
solubility (1.97 mg/mL) and slowest reduction rate (0.9 mmin-1). This high 
solubility allows more compound A14 to dissolve, while its low reduction rate 
facilitates longer survival of compound A14 within the acidic conditions in the 
stomach. These two properties mean that compound A14 reaches the colon in high 
concentration and in its prodrug form, which promotes high cellular uptake and 
provides better efficacy in the treatment of CRC as compared with the other 
platinum(IV) complexes.  
 
Figure 5.8. (Left) Mean tumor diameter per colon in mice. (Middle) Number of tumors per colon 
in mice. (Right) Mean tumor burden = (mean tumor diameter)2 × tumor number. Statistical analysis 




In summary, compound A14 exhibits better in vivo activity than satraplatin, A3 or 
A9 in a colitis-induced CRC model delivered via p.o. dosing despite having a low 
in vitro activity in colorectal cell lines. The high aqueous solubility and slow 
reduction rate are believed to contribute to the superior activity of compound A14. 
Despite these promising results, further pharmacokinetic and pharmacodynamic 
studies should be conducted to confirm its suitability as a clinical candidate. The 
findings of this study demonstrate that in vitro activity should not be the sole factor 
when judging the in vivo efficacy of a drug. This may be why thousands of 
platinum(IV) complexes fail at the in vivo level, where they are judged on far more 
than their in vitro activity. It is plausible to suggest that these compounds fail 
because of their lack of bioavailability or high toxicity. Therefore, equal attention 
should be paid to improving the cytotoxicity and the physicochemical properties 
(e.g. solubility, permeability, aqueous stability and rate of reduction) in these 
platinum(IV) compounds for their clinical applicability.   
 
5.4 Experimental Procedures 
5.4.1 Materials 
Chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA) unless 
otherwise stated. Oxaliplatin and satraplatin were purchased from Merlin 
Chemicals LTD (Liphook, UK). K2PtCl4 was purchased from Furaya Metals 
(Tokyo, Japan). Clinical-grade cisplatin (1 mg/ml) was purchased from Hospira Pty 
Ltd (Melbourne, Australia). Pt(IV) complexes (A3, A9, A14) were prepared as 
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described elsewhere.16 Dulbecco’s modified Eagle’s medium/Ham’s F12 
(DMEM/F12) and soybean trypsin inhibitor were obtained from Gibco (Thermo 
Fisher Scientific, Waltham, MA). ITS Universal Culture Supplement Premix 
containing 5 mg/mL insulin, 5 mg/mL transferrin, 5 ng/mL selenium was obtained 
from Corning (New York, USA). Fetal bovine serum (FBS) was obtained from 
Hyclone (Thermo Fisher Scientific). Thiazolyl blue tetrazolium bromide (MTT) 
was obtained from Duchefa Biochemie (Haarlem, Netherlands). Dextran sodium 
sulfate (DSS) (MW ~40,000) was purchased from Alfa Aesar (Ward Hill, MA, 
USA). Nitric acid (65% to 71%, TraceSELECT Ultra) was obtained from Fluka 
(Sigma-Aldrich) and used without further purification. Platinum and indium 
standards for ICP-MS measurements were obtained from CPI International 
(Amsterdam, The Netherlands). 
 
5.4.2 Instrumentation 
Concentrations of platinum stock solutions were determined externally by the 
Chemical, Molecular and Materials Analysis Centre (National University of 
Singapore) with Optima ICP-OES (Perkin Elmer, Waltham, MA, USA). A Tecan 
M200 plate reader was used to measure UV-Vis absorbance for MTT (Tecan, 
Männedorf, Switzerland). Platinum and indium concentrations in animal tissues 
were determined using an Agilent 7700 Series ICP-MS (Agilent Technologies, 





5.4.3 Cell culture 
All cultures were maintained in a humidified incubator with 5% carbon dioxide at 
37°C unless otherwise stated. Human colon cancer HCT116 cells and human 
colorectal adenocarcinoma HT29 cells were grown in McCoy’s 5A medium 
supplemented with 10% FBS. The immortalized murine transforming growth 
factor-alpha (TGF-α) transgenic hepatocyte TAMH cells were grown in serum-free 
DMEM/F12 supplemented with ITS Universal Culture Supplement Premix, 100 
nM dexamethasone, 10 mM nicotinamide and 0.01% (v/v) gentamicin.  
 
5.4.4 Cell viability assay 
HCT116, HT29 and TAMH cells were seeded at densities of 8.0 × 103, 8.0 × 103, 
1.2 × 103 cells/well, respectively, in 96-well plates. Stock solution of drugs were 
prepared as follows: cisplatin was prepared in 0.9% NaCl, oxaliplatin and 
satraplatin were prepared in ultrapure water, and all platinum(IV) drugs were 
prepared in DMSO (final DMSO concentration was 0.5% (v/v) in medium).  
 
HCT116 and HT29 cells were exposed to drugs at different concentrations for 72 
h. TAMH cells were exposed to drugs at different concentrations for 24 h. After the 
exposure period, the wells were aspirated and replaced with 200 µL of fresh 
medium and 50 µL of 2 mg/mL MTT in PBS. The plates were incubated in the dark 
for 3 h, the medium aspirated, and then incubated with 200 µL DMSO. Cell 
viability was determined by the absorbance at 560 nm. Cell viability is expressed 
as the percent ratio of treated cells normalized over DMSO-treated control cells. 
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IC50 and LC50 values were obtained from the dose-response curves using Graphpad 
Prism 5 (Graphpad Software Inc., San Diego, CA).  
 
5.4.5 Animal experiments 
All animal experiments were carried out in collaboration with Dr. Ho Han Kiat and 
Dr Pang Yi Yun. Female, 7- to 8-week-old C57BL6 mice were purchased from 
InVivos (Singapore). Animals were housed in animal-holding units at the National 
University of Singapore (NUS) at a constant temperature in a 12/12-hour light/dark 
cycle. All animal procedures were carried out according to a protocol approved by 
the National University of Singapore Institutional Animal Care & Use Committee, 
Protocol number R14-266. The mice were acclimatized for 2 weeks following 
arrival before testing. Before the experiment, mice were allowed free access to food 
and water. 
 
5.4.6. Preparation of test compounds for administration 
Test compounds and satraplatin were weighed and suspended in 0.6% methyl 
cellulose (MC) saline solution. The suspension was sonicated for 1 min to 
homogenously distribute the compound. Cisplatin was administered as a 1 mg/mL 
solution. 
 
5.4.7. Toxicity investigation to determine the optimal dose for treatment 
Toxicity investigations were carried out by observing signs of toxicity (>20% 
weight drop, sudden death, etc.) after the administration of compounds to determine 
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preferred dosage and dosing frequency. For intraperitoneal injections (i.p.), two 
mice were allocated to each test compound or positive control. The test compounds, 
cisplatin and satraplatin, were administered as a single dose of 5 mg/kg, once a 
week. After two weeks, if no signs of toxicity were observed, a higher dose (up to 
a maximum of 25 mg/kg) was given. For oral gavage (p.o.), two mice were 
allocated to each test compound or positive control. The test compounds and 
satraplatin were administered to the mice as a single dose of 10 mg/kg, thrice a 
week. After two weeks, if no signs of toxicity were observed (>20% weight drop, 
sudden death, etc.), a higher dose (up to a maximum of 25 mg/kg) was given. 
 
5.4.8 Tissue distribution studies 
Tissue distribution studies were carried out by dosing the mice either via i.p. or p.o. 
routes at the final dosage and dosing frequency determined from the toxicity 
investigation. For i.p. injection, compounds were administered at 15 mg/kg, once a 
week for two weeks (cisplatin was administered at 5 mg/kg, once a week for two 
weeks). For p.o., compounds were administered at 20 mg/kg, thrice a week for two 
weeks. After two weeks, the mice were euthanized via CO2 asphyxiation. The blood, 
brain, liver, kidney, spleen and colon were collected from each mouse, flash-frozen 
in liquid nitrogen and dried under vacuum (except blood). Tissues were then 
weighed, cut up, and digested in concentrated nitric acid at 90°C overnight. 





5.4.9 Optimization of CRC mouse model 
Tumors were induced in the mice by repeated exposure to the inflammatory 
substance DSS after exposure to the carcinogenic AOM. Several combinations of 
the compounds were undertaken to optimize how to induce the formation of at least 
5 to 10 tumors in the mice. On Day 0, mice were given a single dose of 10 mg/kg 
AOM by i.p. injection. On Day 7, mice were given 1.5% DSS in their drinking 
water. On Day 14, mice were given autoclaved drinking water for 2 weeks. This 
constitutes one cycle of AOM/DSS treatment; mice were given either one or two 
of these cycles. Each batch of mice were monitored over 3 months, with three 
animals sacrificed at the end of each month to determine the extent of CRC 
formation. 
 
5.4.10 In vivo evaluation of platinum complexes in optimized CRC model 
There were five arms of the in vivo experiment for p.o. administration: vehicle 
control, three test compounds (A3, A9 and A14) and the positive control, satraplatin. 
Each arm consisted of 6 mice. On Day 0, the mice were given a single dose of 10 
mg/kg AOM via i.p. injection. On Day 7, the mice received 2% DSS in their 
drinking water. On Day 14, mice were given autoclaved drinking water for 2 weeks. 
The mice received a total of three cycles of DSS/water treatment after the injection 
of AOM. On Day 70, mice received 20 mg/kg of a compound or positive control, 
thrice a week for 2 weeks. Vehicle control received 0.6% MC in saline without 
compounds. On Day 84, mice were euthanized by CO2 asphyxiation. The colon was 
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harvested, cleaned and split longitudinally. Tumor number and diameter were 
determined under a dissecting microscope using a digital caliper. 
 
5.4.11 ICP-MS 
All samples were analyzed using an Agilent Technologies 7700 series ICP-MS. 
Platinum and indium were measured at m/z 195 and m/z 115, respectively. Metal 
standards were freshly prepared before each measurement. Platinum at 0, 0.5, 1, 2, 
5, 10, 20, 40 ppb were used for the calibration curve. All readings were made in 
triplicate in He mode.  
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5.6 Supplementary information 
Table S5.1. Platinum content in organs after exposure to satraplatin. 
Satraplatin 
Pt amount/wet weight (ng/mg)a 
Oral gavage Intraperitoneal injection 
Blood 416.86 534.21 2210.86 1691.46 
Liver 6.98 7.87 17.56 11.04 
Kidney 5.04 6.49 13.56 10.72 
Spleen 1.24 1.41 6.28 4.74 
Colon 0.4 0.73 2.7 1.7 
Brain 0.05 0.05 0.09 0.06 
aPlatinum content in organs from four different mice with different dosing methods. 
 
Table S5.2. Platinum content in organs after exposure to A3. 
A3 
Pt amount/wet weight (ng/mg)a 
Oral gavage Intraperitoneal injection 
Blood 799.84 612.61 2344.73 1718.6 
Liver 10.27 11.13 26.1 18.41 
Kidney 7.59 4.3 24.52 17.08 
Spleen 2.65 2.05 9.47 6.92 
Colon 1.26 1.02 5.61 5.41 
Brain 0.04 0.04 0.09 0.07 
aPlatinum content in organs from four different mice with different dosing methods. 
 
Table S5.3. Platinum content in organs after exposure to A9. 
A9 
Pt amount/wet weight (ng/mg)a 
Oral gavage Intraperitoneal injection 
Blood 196.22 179.78 2002.01 1740.82 
Liver 2.15 1.63 14.4 13.19 
Kidney 2.01 1.46 12.57 9.7 
Spleen 0.56 0.55 6.08 6.85 
Colon 0.34 0.27 3.98 3.49 
Brain 0.02 0.02 0.06 0.07 




Table S5.4. Platinum content in organs after exposure to A14. 
A14 
Pt amount/wet weight (ng/mg)a 
Oral gavage Intraperitoneal injection 
Blood 238.25 274.34 1380.49 833.88 
Liver 3.43 3.62 12.9 15.82 
Kidney 1.79 2.16 10.38 9.56 
Spleen 0.64 0.71 3.13 3.82 
Colon 0.39 0.58 2.23 1.92 
Brain 0.02 0.03 0.07 0.1 
aPlatinum content in organs from four different mice with different dosing methods. 
 
Table S5.5. Platinum content in organs after exposure to cisplatin. 
Cisplatin 
Pt amount/wet weight (ng/mg)a 
Intraperitoneal injection 
Blood 571.32 523.65 
Liver 4.38 4.47 
Kidney 3.87 4.17 
Spleen 2.18 1.66 
Colon 0.97 1.2 
Brain 0.08 0.06 
aPlatinum content in organs from two different mice after intraperitoneal injection 
of cisplatin. 
 
Table S5.6. Antitumoral activity of platinum drugs in CRC mouse model 
Compound Tumor numbera  Mean tumor diameter (mm)b 
Vehicle 13 8 15 13 17 13  1.7 2.1 1.6 2.0 1.7 1.8 
Satraplatin 15 22 16 14 13 10  1.5 1.8 1.9 2.2 1.4 1.4 
A3 12 18 13 17 11 16  1.5 1.6 2.1 2.1 1.9 1.5 
A9 8 26 17 33 13 12  1.8 1.8 2.0 1.3 1.2 1.7 
A14 5 16 9 23 19 6  1.2 1.6 1.7 1.4 1.7 1.6 





Table S5.7. Mean tumor burden in mice with colorectal cancer. 
Compound Mean tumor burdena 
Vehicle 39.3 33.6 38.1 53.6 50.7 40.3 
Satraplatin 35.0 67.4 54.8 66.4 24.1 19.3 
A3 26.4 48.3 55.7 74.6 41.2 36.6 
A9 25.6 82.4 67.2 51.9 19.4 33.3 
A14 7.0 41.0 25.0 46.2 55.9 15.0 
aMean tumor burden = (mean tumor diameter)2 × tumor number. 
 
 
Figure S5.1. Images of the colons of mice sacrificed on Days 56 and 84. All mice 
were treated with one cycle of azoxymethane/dextran sodium sulfate. Arrows point 
to the site where the tumor was found. Circled areas denote a cluster of tumors. 
 
 
Figure S5.2. Images of the colons of mice sacrificed on Day 56. All mice were 
treated with two cycles of azoxymethane/dextran sodium sulfate. Arrows point to 




Figure S5.3. Images of the colons of mice sacrificed on Day 84. All mice were 
treated with three cycles of azoxymethane/dextran sodium sulfate. Arrows point to 




Figure S5.4. Individual images of mouse colons after 2 weeks of treatment with 
vehicle and/or platinum complexes. C1 to C6 represent the cage number. The 




Conclusions and Future Directions 
 
The clinical use of cisplatin is facing significant challenges, including the development of tumor 
resistance to the drug and serious toxicity and side-effects that hinder patient quality of life. These 
concerns led to the design and production of platinum(IV) complexes that release the cytotoxic 
cisplatin core following biological reduction at or close to the site of application. This slight 
difference in drug design is thought to significantly improve uptake, delivery and action; yet, the 
optimal design for such complexes is still unclear. This thesis sought to explore the properties that 
are essential for the development of clinically relevant platinum(IV) complexes. Platinum(IV) 
complexes comprise axial ligands that can be adjusted to modulate the solubility, permeability, 
reduction potential, aqueous stability, and cytotoxicity of the drug without directly modifying the 
platinum(II) pharmacophore. The first arm of this project examined how lipophilicity affected the 
cellular accumulation of the drug and its cytotoxicity, complemented by fluorescence imaging. 
The second arm of this project emphasized the importance of a range of physicochemical 
properties aside from in vitro cytotoxicity in drug design, as these additional properties should be 
considered during in vivo testing. These findings will hopefully pave the way for the design of 
better platinum(IV) anticancer drugs. 
 
The formation of platinated DNA adducts influences the cellular sensitivity to platinum treatment, 
and this justifies the importance of achieving high levels of platinum accumulation in the cell. Four 
inert platinum(IV) complexes (A1, A3, A4 and PtBz) with different lipophilicity were tested for 
rates of cellular accumulation (Chapters 2). These platinum(IV) complexes bear simple 
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carboxylate ligands that have no known biological targeting effects, and their asymmetric design 
can facilitate fine-tuning of the drug to improve lipophilicity.  Cellular accumulation was found to 
increase linearly with lipophilicity. PtBz was the most lipophilic compound, achieving the highest 
cellular platinum accumulation in the ovarian cancer cell lines studied. Notably, cisplatin had a 
higher nuclear platinum accumulation than complex A1, explaining its superior in vitro 
cytotoxicity and why the formation of platinum-DNA adducts is so important. Further analysis 
indicates that these platinum(IV) complexes are taken up passively into the cells, where they then 
undergo intracellular reduction and aquation to form the active platinum(II) species. This energy-
independent uptake along with reduced efflux of the positively charged platinum(II) species leads 
to a net increase in cellular accumulation.  
 
The next question was to ascertain how high cellular accumulation (due to increased lipophilicity) 
translates into cytotoxicity (Chapter 3). Cytotoxicity from the platinum(IV) complexes increased 
linearly with lipophilicity (and, thus, cellular accumulation), and, like cisplatin, these platinum(IV) 
complexes induced apoptotic cell death and cell cycle arrest at G2/M. However, the increased 
lipophilicity and cellular platinum accumulation caused a shift in the dependence on p53 in 
transducing the apoptosis signaling pathway. Since p53 is often loss or mutated in cisplatin-
resistant cancers, it would be interesting to create lipophilic platinum(IV) complexes with a 
reduced dependency on p53-mediated apoptosis to ultimately overcome cisplatin-resistance.    
 
The application of Rho-DDTC showed high cellular accumulation of platinum(II) complexes (e.g., 
cisplatin) and the reduced species of platinum(IV) complexes (Chapter 4). In particular, the 
reduced species of lipophilic PtBz platinum(IV) complex accumulated around the nucleus, which 
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prompted a high level of DNA platination. This observation complemented earlier findings 
(Chapters 2 and 3), with cellular accumulation and cytotoxicity highest for PtBz among the 
platinum(IV) complexes studied.  
 
Besides proving lipophilicity as a key parameter for efficacy in vitro, other physicochemical 
properties were evaluated for their efficacy in vivo (Chapter 5). Lessons learned from studying the 
platinum(IV) complexes that failed in clinical trials suggested that premature reduction and 
insufficient accumulation of the drug contributed to the drug’s lower efficacy. The purpose-
designed asymmetric-platinum(IV) complexes offered a versatile platform to overcome these 
concerns, with the addition of two axial ligands that could be independently modified to achieve 
the desired pharmacokinetic and biological activity of the drug. Three asymmetric-platinum(IV) 
complexes (A3, A9 and A14) were evaluated in vivo in a colorectal cancer model and their 
efficacies compared against satraplatin. Among the platinum(IV) complexes evaluated, complex 
A14 exhibited the best in vivo activity despite being least cytotoxic in colorectal cell lines in vitro. 
Its high aqueous solubility and slower reduction rate were the two key factors that dictated the in 
vitro efficacy of the A14 complex. These results highlight the limitation in using in vitro 
cytotoxicity assays to screen for potential anticancer drugs. Hence, a better strategy in designing 
platinum(IV) complexes is needed, where the physicochemical properties can be evaluated and 
improved alongside measures of cytotoxicity. 
 
There were several limitations in this study. First, the existence of an energy-dependent and/or 
carrier-mediated uptake pathway was not evaluated in the uptake of platinum(IV) complexes. As 
such, the involvement of these pathways cannot be ruled out completely. A comprehensive 
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examination of the active and carrier-mediated uptake of platinum(IV) complexes should be 
carried out in the future. Second, the apoptotic signaling pathway(s) of these platinum(IV) 
complexes in ovarian cancer cell lines was not explored in detailed, and it remains to be determined 
how platinum(IV) complexes can have an effect in cisplatin-resistant ovarian cancer. Future study 
of these platinum(IV) complexes should explore the detailed molecular pathway(s) of these 
platinum(IV) complexes. Indeed, the results in Chapter 2 point to a reduced accumulation of 
platinum(IV) complexes in the cisplatin-resistant ovarian cancer cells, but why this occurred 
remains unknown. Assessing why this resistant cell line has a reduced cellular accumulation of 
platinum(IV) complexes may provide further insight into the mode of resistance in ovarian cancer 
cells and, perhaps, in other tissue types that demonstrate cisplatin resistance. Third, protein 
expression changes were not explored in the in vivo study, and thus it remains unclear whether the 
molecular mechanism uncovered in the ovarian cancer cells in vitro translates to that in colon 
cancer cells or in tissues in the mouse model. Future studies should aim to explore the mechanism 
of action of these compounds in an in vivo cancer model. 
 
This thesis highlighted the importance of optimizing cytotoxicity (through increase lipophilicity) 
as well as a range of other physicochemical properties (solubility, aqueous stability, lipophilicity, 
and reduction potential) when designing clinically relevant platinum(IV) complexes. Looking 
forward, the same strategy can be applied for the design of platinum(IV) complexes with an 
oxaliplatin core. Oxaliplatin exhibits a spectrum of activity different from that of cisplatin, with 
little to no cross resistance with cisplatin. In an extension of the findings presented here, it is 
reasonable to suggest that platinum(IV) prodrugs with an oxaliplatin core could improve the 
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efficacy currently seen with oxaliplatin treatment. The strategy optimized in this thesis may well 
be translated into the oxaliplatin system and fast forward the drug discovery process. 
